Document And Entity Information
Document And Entity Information | 6 Months Ended |
Mar. 31, 2023 shares | |
Cover [Abstract] | |
Entity Registrant Name | ASHLAND INC. |
Entity Central Index Key | 0001674862 |
Current Fiscal Year End Date | --09-30 |
Entity Current Reporting Status | Yes |
Entity Filer Category | Large Accelerated Filer |
Entity Small Business | false |
Entity Emerging Growth Company | false |
Entity File Number | 333-211719 |
Entity Tax Identification Number | 81-2587835 |
Entity Address, Address Line One | 8145 Blazer Drive |
Entity Address, City or Town | Wilmington |
Entity Address, State or Province | DE |
Entity Address, Postal Zip Code | 19808 |
Entity Shell Company | false |
Entity Interactive Data Current | Yes |
Document Quarterly Report | true |
Document Transition Report | false |
City Area Code | 302 |
Local Phone Number | 995-3000 |
Entity Common Stock, Shares Outstanding | 52,800,273 |
Document Fiscal Year Focus | 2023 |
Document Fiscal Period Focus | Q2 |
Trading Symbol | ASH |
Title of 12(b) Security | Common Stock, par value $.01 per share |
Security Exchange Name | NYSE |
Document Type | 10-Q |
Amendment Flag | false |
Document Period End Date | Mar. 31, 2023 |
Entity Incorporation, State or Country Code | DE |
STATEMENTS OF CONSOLIDATED COMP
STATEMENTS OF CONSOLIDATED COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Statement of Comprehensive Income [Abstract] | ||||
Sales | $ 603 | $ 604 | $ 1,128 | $ 1,115 |
Cost of sales | 406 | 384 | 766 | 735 |
Gross profit | 197 | 220 | 362 | 380 |
Selling, general and administrative expense | 79 | 90 | 172 | 172 |
Research and development expense | 12 | 13 | 25 | 26 |
Intangibles amortization expense - Note G | 23 | 24 | 46 | 47 |
Equity and other income | 0 | 0 | 1 | 0 |
Income on acquisitions and divestitures, net - Note B | 0 | 7 | 0 | 7 |
Operating income | 83 | 100 | 120 | 142 |
Net interest and other expense (income) | (10) | 43 | (24) | 49 |
Other net periodic benefit loss (income) | 2 | (1) | 3 | (1) |
Income from continuing operations before income taxes | 91 | 58 | 141 | 94 |
Income tax expense (benefit) - Note J | (1) | 20 | 7 | 24 |
Income from continuing operations | 92 | 38 | 134 | 70 |
Income (loss) from discontinued operations (net of income taxes) - Note C | (1) | 748 | (2) | 764 |
Net income | $ 91 | $ 786 | $ 132 | $ 834 |
Basic earnings per share - Note M | ||||
Income from continuing operations | $ 1.71 | $ 0.67 | $ 2.47 | $ 1.22 |
Income (loss) from discontinued operations | (0.01) | 13.23 | (0.04) | 13.48 |
Net income | 1.70 | 13.90 | 2.43 | 14.70 |
Diluted earnings per share - Note M | ||||
Income from continuing operations | 1.68 | 0.66 | 2.43 | 1.20 |
Income (loss) from discontinued operations | (0.01) | 13.03 | (0.04) | 13.25 |
Net income | $ 1.67 | $ 13.69 | $ 2.39 | $ 14.45 |
COMPREHENSIVE INCOME | ||||
Net income | $ 91 | $ 786 | $ 132 | $ 834 |
Other comprehensive income (loss), net of tax | ||||
Unrealized translation gain (loss) | 27 | (5) | 109 | (21) |
Unrealized gains (losses) on commodity hedges | (3) | 5 | (7) | 1 |
Other comprehensive income (loss) - Note N | 24 | 0 | 102 | (20) |
Comprehensive income | $ 115 | $ 786 | $ 234 | $ 814 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 | |
Current assets | |||
Cash and cash equivalents | $ 399 | $ 646 | |
Accounts receivable - Note H | [1] | 395 | 402 |
Inventories - Note F | 730 | 629 | |
Other assets | 107 | 91 | |
Total current assets | 1,631 | 1,768 | |
Property, plant and equipment | |||
Cost | 3,164 | 3,050 | |
Accumulated depreciation | 1,813 | 1,712 | |
Net property, plant and equipment | 1,351 | 1,338 | |
Goodwill - Note G | 1,385 | 1,312 | |
Intangibles - Note G | 940 | 963 | |
Operating lease assets, net - Note I | 124 | 107 | |
Restricted investments - Note E | 349 | 313 | |
Asbestos insurance receivable - Note L | [2] | 133 | 138 |
Deferred income taxes | 20 | 20 | |
Other assets | 250 | 254 | |
Total noncurrent assets | 4,552 | 4,445 | |
Total assets | 6,183 | 6,213 | |
Current liabilities | |||
Trade and other payables | 246 | 265 | |
Accrued expenses and other liabilities | 206 | 269 | |
Current operating lease obligations - Note I | 20 | 19 | |
Total current liabilities | 472 | 553 | |
Noncurrent liabilities | |||
Long-term debt - Note H | 1,328 | 1,270 | |
Asbestos litigation reserve - Note L | 443 | 472 | |
Deferred income taxes | 175 | 176 | |
Employee benefit obligations - Note K | 110 | 103 | |
Operating lease obligations - Note I | 108 | 94 | |
Other liabilities | 280 | 325 | |
Total noncurrent liabilities | 2,444 | 2,440 | |
Commitments and contingencies - Note L | |||
Stockholders' equity - Note N | 3,267 | 3,220 | |
Total liabilities and stockholders' equity | $ 6,183 | $ 6,213 | |
[1] Accounts receivable includes an allowance for credit losses of $ 4 million at both March 31, 2023 and September 30, 2022 . Asbestos insurance receivable includes an allowance for credit losses of $ 3 million at both March 31, 2023 and September 30, 2022 . |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Current assets | ||
Allowance for credit losses on Accounts receivables | $ 4 | $ 4 |
Noncurrent assets | ||
Allowance for credit losses on Asbestos insurance receivable | $ 3 | $ 3 |
STATEMENTS OF CONDENSED CONSOLI
STATEMENTS OF CONDENSED CONSOLIDATED CASH FLOWS (unaudited) - USD ($) $ in Millions | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | ||
CASH FLOWS PROVIDED (USED) BY OPERATING ACTIVITIES FROM CONTINUING OPERATIONS | |||
Net income | $ 132 | $ 834 | |
Loss (Income) from discontinued operations (net of income taxes) | 2 | (764) | |
Adjustments to reconcile income from continuing operations to cash flows from operating activities: | |||
Depreciation and amortization | 120 | 121 | |
Original issue discount and debt issuance costs amortization | 3 | 3 | |
Deferred income taxes | 15 | (3) | |
Stock based compensation expense | 12 | 9 | |
Excess tax benefit on stock based compensation | 2 | 1 | |
Loss (Income) from restricted investments | (48) | 14 | |
Asset impairments | 4 | ||
Pension contributions | (3) | (3) | |
Gain on pension and other postretirement plan remeasurements | (1) | ||
Change in operating assets and liabilities | [1] | (212) | (180) |
Total cash flows provided by operating activities from continuing operations | 27 | 31 | |
CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES FROM CONTINUING OPERATIONS | |||
Additions to property, plant and equipment | (58) | (37) | |
Proceeds from disposal of property, plant and equipment | 11 | ||
Proceeds from settlement of company-owned life insurance contracts | 3 | ||
Company-owned life insurance payments | (1) | ||
Funds restricted for specific transactions | (5) | (44) | |
Reimbursements from restricted investments | 16 | 28 | |
Proceeds from sale of securities | 15 | 46 | |
Purchases of securities | (15) | (46) | |
Total cash flows used by investing activities from continuing operations | (45) | (42) | |
CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES FROM CONTINUING OPERATIONS | |||
Repurchase of common stock | (142) | (155) | |
Repayment of long-term debt | (250) | ||
Repayment of short-term debt | (365) | ||
Cash dividends paid | (36) | (34) | |
Stock based compensation employee withholding taxes paid in cash | (10) | (6) | |
Total cash flows used by financing activities from continuing operations | (188) | (810) | |
CASH USED BY CONTINUING OPERATIONS | (206) | (821) | |
Cash provided (used) by discontinued operations | |||
Operating cash flows | (47) | (73) | |
Investing cash flows | 0 | 1,650 | |
Total cash provided (used) by discontinued operations | (47) | 1,577 | |
Effect of currency exchange rate changes on cash and cash equivalents | 6 | (2) | |
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (247) | 754 | |
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD | 646 | 210 | |
CASH AND CASH EQUIVALENTS - END OF PERIOD | $ 399 | $ 964 | |
[1] Excludes changes resulting from operations acquired, sold or held for sale. |
Significant Accounting Policies
Significant Accounting Policies | 6 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Significant Accounting Policies | NOTE A – SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial reporting and Securities and Exchange Commission (SEC) regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. These statements omit certain information and footnote disclosures required for complete annual financial statements and, therefore, should be read in conjunction with the Ashland Inc. and consolidated subsidiaries (Ashland) Annual Report on Form 10-K for the fiscal year ended September 30, 2022. Results of operations for the period ended March 31, 2023 are not necessarily indicative of the expected results for the remaining quarters in the fiscal year. Ashland is comprised of the following reportable segments: Life Sciences, Personal Care, Specialty Additives and Intermediates. Unallocated and Other includes corporate governance activities and certain legacy matters. For additional information, see Note Q. Use of estimates, risks and uncertainties The preparation of Ashland’s Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales and expenses, and the disclosures of contingent assets and liabilities. Significant items that are subject to such estimates and assumptions include, but are not limited to, environmental remediation, asbestos litigation, the accounting for goodwill and other intangible assets, and income taxes. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ significantly from the estimates under different assumptions or conditions. Ashland’s results are affected by domestic and international economic, political, legislative, regulatory and legal actions. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, government fiscal policies and changes in the prices of certain key raw materials, can have a significant effect on operations. While Ashland maintains reserves for anticipated liabilities and carries various levels of insurance, Ashland could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings relating to asbestos, environmental remediation or other matters. New accounting pronouncements A description of new U.S. GAAP accounting standards issued or adopted during the current year is required in interim financial reporting. A detailed listing of new accounting standards relevant to Ashland is included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2022 . There were no new standards that were either issued or adopted in the current fiscal year that will have a material impact on Ashland's consolidated financial statements. |
Divestitures
Divestitures | 6 Months Ended |
Mar. 31, 2023 | |
Divestitures [Abstract] | |
Divestitures | NOTE B – DIVESTITURES Performance Adhesives On February 28, 2022, Ashland completed the sale of its Performance Adhesives business to Arkema, a French société anonyme. Proceeds from the sale were approximately $ 1.7 billion, net of transaction costs. Ashland recognized a $ 732 million gain on sale within the Income (Loss) from Discontinued Operations caption of the Statements of Consolidated Comprehensive Income (Loss) for the three and six months ended March 31, 2022. The transaction represented a strategic shift in Ashland’s business and had a major effect on Ashland’s operations and financial results. Accordingly, the operating results and cash flows related to Performance Adhesives have been reflected as discontinued operations in the Statements of Consolidated Comprehensive Income (Loss) and Statements of Condensed Consolidated Cash Flows. See Note C for the results of operations for Performance Adhesives for all affected periods. Certain indirect corporate costs included within the selling, general and administrative expense caption of the Statements of Consolidated Comprehensive Income (Loss) that were previously allocated to the Performance Adhesives segment do not qualify for classification within discontinued operations and are now reported as selling, general and administrative expense within continuing operations on a consolidated basis and within the Unallocated and other segment. There were no such costs for the three and six months ended March 31, 2023 and $ 3 million and $ 7 million for the three and six months ended March 31, 2022, respectively. Other manufacturing facility sales During the December 2022 quarter, Ashland entered into a definitive sale agreement to sell a Specialty Additives manufacturing facility for less than $ 1 million. The net asset value related to these sites was less than $ 1 million and $ 4 million at March 31, 2023 and September 30, 2022, respectively. During the three and six months ended March 31, 2023 , no impairment charges and $ 4 million of impairment charges, respectively, were recorded within the selling, general and administrative expense caption of the Statement of Consolidated Comprehensive Income (Loss) for this manufacturing facility. Other corporate assets During the three and six months ended March 31, 2022, Ashland completed a sale of excess land. Ashland received net proceeds of approximately $ 11 million and recorded a pre-tax gain of $ 7 million within the Income on acquisitions and divestitures, net caption of the Statements of Consolidated Comprehensive Income (Loss) for the three and six months ended March 31, 2022. |
Discontinued Operations
Discontinued Operations | 6 Months Ended |
Mar. 31, 2023 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Discontinued Operations | NOTE C– DISCONTINUED OPERATIONS Ashland has divested certain businesses that have qualified as discontinued operations. The operating results from these divested businesses and subsequent adjustments related to ongoing assessments of certain retained liabilities and tax items have been recorded within the discontinued operations caption in the Statements of Consolidated Comprehensive Income (Loss) for all periods presented. Components of amounts reflected in the Statements of Consolidated Comprehensive Income (Loss) related to discontinued operations are presented in the following table for the three and six months ended March 31, 2023 and 2022. Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Income (loss) from discontinued operations (net of tax) Performance Adhesives $ — $ 17 $ — $ 34 Composites/Marl facility ( 1 ) — ( 1 ) — Distribution — ( 1 ) ( 1 ) ( 2 ) Gain on disposal of discontinued operations (net of tax) Performance Adhesives — 732 — 732 $ ( 1 ) $ 748 $ ( 2 ) $ 764 The following table presents a reconciliation of the captions within Ashland's Statements of Consolidated Comprehensive Income (Loss) for the income (loss) from discontinued operations attributable to Performance Adhesives for the three and six months ended March 31, 2022. This disclosure was not applicable for the three and six months ended March 31, 2023 as a result of the sale in fiscal 2022. Three months ended Six months ended March 31 March 31 (In millions) 2022 2022 Income (loss) from discontinued operations attributable to Performance Adhesives Sales $ 75 $ 171 Cost of sales ( 56 ) ( 122 ) Selling, general and administrative expense ( 6 ) ( 11 ) Research and development expense ( 1 ) ( 3 ) Pretax income of discontinued operations 12 35 Income tax (expense) benefit 5 ( 1 ) Income from discontinued operations $ 17 $ 34 |
Restructuring Activities
Restructuring Activities | 6 Months Ended |
Mar. 31, 2023 | |
Restructuring and Related Activities [Abstract] | |
Restructuring Activities | NOTE D – RESTRUCTURING ACTIVITIES Fiscal 2023 Life Sciences restructuring program During December 2022, Ashland implemented a restructuring program within the Nutraceuticals business of the Life Sciences segment. Ashland recorded severance expense of zero and $ 1 million during the three and six months ended March 31, 2023 . As of March 31, 2023, the severance reserve associated with this program was less than $ 1 million. |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Mar. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | NOTE E – FAIR VALUE MEASUREMENTS Ashland uses applicable guidance for defining fair value, the initial recording and periodic remeasurement of certain assets and liabilities measured at fair value and related disclosures for instruments measured at fair value. Fair value accounting guidance establishes a fair value hierarchy, which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). An instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the instrument’s fair value measurement. The three levels within the fair value hierarchy are described as follows. Level 1 – Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3 – Unobservable inputs for the asset or liability for which there is little, if any, market activity at the measurement date. Unobservable inputs reflect Ashland’s own assumptions about what market participants would use to price the asset or liability. The inputs are developed based on the best information available in the circumstances, which might include Ashland’s own financial data such as internally developed pricing models, discounted cash flow methodologies, as well as instruments for which the fair value determination requires significant management judgment. For assets that are measured using quoted prices in active markets (Level 1), the total fair value is the published market price per unit multiplied by the number of units held without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs (Level 2) are primarily valued by reference to quoted prices of similar assets or liabilities in active markets, adjusted for any terms specific to that asset or liability. For all other assets and liabilities for which unobservable inputs are used (Level 3), fair value is derived using fair value models, such as a discounted cash flow model or other standard pricing models that Ashland deems reasonable. The following table summarizes financial instruments subject to recurring fair value measurements as of March 31, 2023. Carrying Total Quoted prices Significant Significant (In millions) value value Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 399 $ 399 $ 399 $ — $ — Restricted investments (a) (b) 410 410 410 — — Investment of captive insurance company (c) 4 4 4 — — Foreign currency derivatives (d) 2 2 — 2 — Total assets at fair value $ 815 $ 815 $ 813 $ 2 $ — Liabilities Foreign currency derivatives (e) $ 2 $ 2 $ — $ 2 $ — Commodity derivatives (e) 6 6 — 6 — Total liabilities at fair value $ 8 $ 8 $ — $ 8 $ — (a) Included in restricted investments and $ 61 million within other current assets in the Condensed Consolidated Balance Sheets . (b) Includes $ 267 million related to the Asbestos trust and $ 143 million related to the Environmental trust . (c) Included in other noncurrent assets in the Condensed Consolidated Balance Sheets . (d) Included in accounts receivable in the Condensed Consolidated Balance Sheets . (e) Included in accrued expenses and other liabilities in the Condensed Consolidated Balance Sheets. The following table summarizes financial asset instruments subject to recurring fair value measurements as of September 30, 2022. Carrying Total Quoted prices Significant Significant (In millions) value value Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 646 $ 646 $ 646 $ — $ — Restricted investments (a) (b) 374 374 374 — — Investment of captive insurance company (c) 9 9 9 — — Foreign currency derivatives (d) 1 1 — 1 — Commodity derivatives (d) 4 4 — 4 — Total assets at fair value $ 1,034 $ 1,034 $ 1,029 $ 5 $ — Liabilities Foreign currency derivatives (e) $ 9 $ 9 $ — $ 9 $ — Commodity derivatives (e) 1 1 — 1 — Total liabilities at fair value $ 10 $ 10 $ — $ 10 $ — (a) Included in restricted investments and $ 61 million within other current assets in the Condensed Consolidated Balance Sheets . (b) Includes $ 245 million related to the Asbestos trust and $ 129 million related to the Environmental trust . (c) Included in other noncurrent assets in the Condensed Consolidated Balance Sheets . (d) Included in accounts receivable in the Condensed Consolidated Balance Sheets . (e) Included in accrued expenses and other liabilities in the Condensed Consolidated Balance Sheets. Restricted investments Ashland maintains certain investments in a company restricted renewable annual trusts for the purpose of paying future asbestos indemnity and defense costs and future environmental remediation and related litigation costs. The financial instruments are designated as investment securities, classified as Level 1 measurements within the fair value hierarchy. These securities were classified primarily as noncurrent restricted investment assets, with $ 61 million classified within other current assets, in the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022. The following table presents gross unrealized gains and losses for the restricted securities as of March 31, 2023 and September 30, 2022: Gross Gross (In millions) Adjusted Cost Unrealized Gain Unrealized Loss Fair Value As of March 31, 2023 Demand deposit $ 12 $ — $ — $ 12 Equity mutual fund 177 27 ( 4 ) 200 Fixed income mutual fund 234 — ( 36 ) 198 Fair value $ 423 $ 27 $ ( 40 ) $ 410 As of September 30, 2022 Demand deposit $ 6 $ — $ — $ 6 Equity mutual fund 186 20 ( 25 ) 181 Fixed income mutual fund 234 — ( 47 ) 187 Fair value $ 426 $ 20 $ ( 72 ) $ 374 The following table presents the investment income, net gains and losses realized, funds restricted for specific transactions, and disbursements related to the investments within the portfolio for the three and six months ended March 31, 2023 and 2022. Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Investment income (a) $ 3 $ 2 $ 6 $ 10 Net gains (losses) (a) 19 ( 28 ) 41 ( 24 ) Funds restricted for specific transactions — 44 5 44 Disbursements ( 16 ) ( 21 ) ( 16 ) ( 28 ) (a) Included in the net interest and other expense (income) caption within the Statements of Consolidated Comprehensive Income (Loss). Foreign currency derivatives Ashland conducts business in a variety of foreign currencies. Accordingly, Ashland regularly uses foreign currency derivative instruments to manage exposure on certain transactions denominated in foreign currencies to curtail potential earnings volatility effects on certain assets and liabilities, including short-term inter-company loans, denominated in currencies other than Ashland’s functional currency of an entity. These derivative contracts generally require exchange of one foreign currency for another at a fixed rate at a future date and generally have maturities of less than twelve months. All contracts are valued at fair value with net changes in fair value recorded within the selling, general and administrative expense caption. The impacts of these contracts were largely offset by gains and losses resulting from the impact of changes in exchange rates on transactions denominated in non-functional currencies. The following table summarizes the net gains and losses recognized during the three and six months ended March 31, 2023 and 2022 within the Statements of Consolidated Comprehensive Income (Loss). Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Foreign currency derivative gains (losses) $ 1 $ ( 11 ) $ 9 $ ( 9 ) The following table summarizes the fair values of the outstanding foreign currency derivatives as of March 31, 2023 and September 30, 2022 included in accounts receivable and accrued expenses and other liabilities of the Condensed Consolidated Balance Sheets. March 31 September 30 (In millions) 2023 2022 Foreign currency derivative assets $ 2 $ 1 Notional contract values 189 133 Foreign currency derivative liabilities $ 2 $ 9 Notional contract values 140 535 Commodity derivatives To manage its exposure to the market price volatility of natural gas consumed by its U.S. plants during the manufacturing process, Ashland regularly enters into forward contracts that are designated as cash flow hedges. The following table summarizes the net gai ns and losses recognized during the three and six months ended March 31, 2023 and 2022 within the cost of sales caption of the Statements of Consolidated Comprehensive Income (Loss). Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Commodity derivative gains (losses) $ ( 1 ) $ 2 $ — $ 4 The following table summarizes the fair values of the outstanding commodity derivatives as of March 31, 2023, and September 30, 2022 included in accounts receivable and accrued expenses and other liabilities of the Condensed Consolidated Balance Sheets. March 31 September 30 (In millions) 2023 2022 Commodity derivative assets $ — $ 4 Notional contract values 1 13 Commodity derivative liabilities $ 6 $ 1 Notional contract values 21 9 Other financial instruments At March 31, 2023 and September 30, 2022 , Ashland's long-term debt (including the current portion and excluding debt issuance cost discounts) had a carrying value of $ 1,342 million and $ 1,284 million, respectively, compared to a fair value of $ 1,224 million and $ 1,102 million, respectively. The fair values of long-term debt are based on quoted market prices or, if market prices are not available, the present values of the underlying cash flows discounted at Ashland’s incremental borrowing rates. The carrying value of long-term debt with variable interest approximated fair value. |
Inventories
Inventories | 6 Months Ended |
Mar. 31, 2023 | |
Inventory Disclosure [Abstract] | |
Inventories | NOTE F – INVENTORIES Inventories are carried at the lower of cost or net realizable value. Inventories are stated at cost using the weighted-average cost method. This method values inventories using average costs for raw materials and most recent production costs for labor and overhead. The following table summarizes Ashland’s inventories as of the reported Condensed Consolidated Balance Sheet dates. March 31 September 30 (In millions) 2023 2022 Finished products $ 472 $ 391 Raw materials, supplies and work in process 258 238 $ 730 $ 629 |
Goodwill and Other Intangibles
Goodwill and Other Intangibles | 6 Months Ended |
Mar. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Other Intangibles | NOTE G – GOODWILL AND OTHER INTANGIBLES Goodwill Ashland tests goodwill and other indefinite-lived intangible assets for impairment annually as of July 1 and when events and circumstances indicate an impairment may have occurred. N o indicators of impairment were identified in the three and six months ended March 31, 2023 . The following is a progression of goodwill by reportable segment for the six months ended March 31, 2023. Life Personal Specialty (In millions) Sciences Care (a) Additives (a) Intermediates (a) Total Balance at September 30, 2022 $ 787 $ 118 $ 407 $ — $ 1,312 Currency translation 45 6 22 — 73 Balance at March 31, 2023 $ 832 $ 124 $ 429 $ — $ 1,385 (a) As of March 31, 2023 and September 30, 2022, there were accumulated impairments of $ 356 million, $ 174 million and $ 90 million related to the Personal Care, Specialty Additives and Intermediates reportable segments, respectively. Other intangible assets Intangible assets principally consist of trademarks and trade names, intellectual property and customer and supplier relationships. Intangible assets classified as finite are amortized on a straight-line basis over their estimated useful lives. The cost of trademarks and trade names is amortized principally over 3 to 20 years , intellectual property over 3 to 20 years , and customer and supplier relationships over 10 to 24 years . Ashland annually reviews, as of July 1, indefinite-lived intangible assets for possible impairment or whenever events or changes in circumstances indicate that carrying amounts may not be recoverable. No indicators of impairment were identified in the three and six months ended March 31, 2023 . Other intangible assets were comprised of the following as of March 31, 2023 and September 30, 2022. March 31, 2023 Gross Net carrying Accumulated carrying (In millions) amount amortization amount Definite-lived intangibles Trademarks and trade names $ 98 $ ( 40 ) $ 58 Intellectual property 738 ( 561 ) 177 Customer and supplier relationships 830 ( 403 ) 427 Total definite-lived intangibles 1,666 ( 1,004 ) 662 Indefinite-lived intangibles Trademarks and trade names 278 — 278 Total intangible assets $ 1,944 $ ( 1,004 ) $ 940 September 30, 2022 Gross Net carrying Accumulated carrying (In millions) amount amortization amount Definite-lived intangibles Trademarks and trade names $ 95 $ ( 37 ) $ 58 Intellectual property 718 ( 523 ) 195 Customer and supplier relationships 801 ( 369 ) 432 Total definite-lived intangibles 1,614 ( 929 ) 685 Indefinite-lived intangibles Trademarks and trade names 278 — 278 Total intangible assets $ 1,892 $ ( 929 ) $ 963 Amortization expense recognized on intangible assets was $ 23 million and $ 24 million for the three months ended March 31, 2023 and 2022, respectively, and $ 46 million and $ 47 million for the six months ended March 31, 2023 and 2022, respectively, and is included in the intangibles amortization expense caption of the Statements of Consolidated Comprehensive Income (Loss). Estimated amortization expense for future periods is $ 93 million in 2023 (includes six months actual and six months estimated), $ 79 million in 2024, $ 74 million in 2025, $ 71 million in 2026 and $ 50 million in 2027. Actual amounts may change from such estimated amounts due to fluctuations in foreign currency exchange rates, additional intangible asset acquisitions and divestitures, potential impairment, accelerated amortization, or other events. |
Debt and Other Financing Activi
Debt and Other Financing Activities | 6 Months Ended |
Mar. 31, 2023 | |
Debt Disclosure [Abstract] | |
Debt and Other Financing Activities | NOTE H – DEBT AND OTHER FINANCING ACTIVITIES The following table summarizes Ashland’s current and long-term debt as of the dates reported in the Condensed Consolidated Balance Sheets. (In millions) March 31, 2023 September 30, 2022 3.375 % Senior Notes, due 2031 $ 450 $ 450 2.00 % Senior Notes, due 2028 (Euro 500 million principal) 545 489 6.875 % notes, due 2043 282 282 6.50 % junior subordinated notes, due 2029 62 60 Other (a) ( 11 ) ( 11 ) Total debt 1,328 1,270 Short-term debt (includes current portion of long-term debt) — — Long-term debt (less current portion) $ 1,328 $ 1,270 (a) Other includes $ 14 million of debt issuance costs as of March 31, 2023 and September 30, 2022 , respectively. The scheduled aggregate maturities to 2027 for long-term debt by year (including the current portion and excluding debt issuance costs) are as follows as of March 31, 2023 : zero in the next 4 years and $ 4 million in 2027. Accounts Receivable Facilities and Off-Balance Sheet Arrangements U.S. Accounts Receivable Sales Program Ashland continues to maintain its U.S. Accounts Receivable Sales Program entered into during fiscal 2021. Ashland accounts for the receivables transferred to buyers as sales. Ashland recognizes any gains or losses based on the excess of proceeds received net of buyer’s discounts and fees compared to the carrying value of the assets. Proceeds received, net of buyer’s discounts and fees, are recorded within the operating activities of the Statements of Condensed Consolidated Cash Flows. Losses on sale of assets, including related transaction expenses are recorded within the net interest and other expense (income) caption of the Statements of Consolidated Comprehensive Income (Loss). Ashland regularly assesses its servicing obligations and records them as assets or liabilities when appropriate. Ashland also monitors its obligation with regards to the limited guarantee and records the resulting guarantee liability when warranted. When applicable, Ashland discloses the amount of the receivable that serves as over-collateralization as a restricted asset. Ashland recognized a loss of less than $ 1 million within the Statements of Consolidated Comprehensive Income (Loss) for the three months ended March 31, 2023 and March 31, 2022, respectively, and $ 1 million and less than $ 1 million for the six months ended March 31, 2023 and March 31, 2022, respectively, within the net interest and other expense (income) caption associated with sales under the program. Ashland has recorded $ 88 million in sales at March 31, 2023 against the buyer’s limit, which was $ 125 million at March 31, 2023 compared to $ 110 million of sales at September 30, 2022 against the buyer's limit, which was $ 125 million at September 30, 2022. Ashland transferred $ 113 million and $ 136 million in receivables to the special purpose entity (SPE) as of March 31, 2023 and September 30, 2022, respectively. Ashland recorded liabilities related to its service obligations and limited guarantee as of March 31, 2023 and September 30, 2022 of less than $ 1 million. As of March 31, 2023 , the year-to-date gross cash proceeds received for receivables transferred and derecognized was $ 99 million, of which $ 122 million was collected, which includes collections from the sales in prior year transferred to the buyer. The difference of $ 22 million represents the impact of a net reduction in accounts receivable sales volume during the current year. On April 14, 2023, Ashland entered into Second and Third Amendments associated with this current program. As part of this amendment the buyer's limit was reduced to $ 115 million between April and October of each year, and up to $ 100 million at all other times. Additionally, the scheduled termination date was extended from May 31, 2023 to April 14, 2025. Foreign Accounts Receivable Securitization Facility Ashland continues to maintain its Foreign 2018 Accounts Receivable Securitization Facility. Ashland accounts for the Foreign 2018 Accounts Receivable Securitization Facility as secured borrowings, and the receivables sold pursuant to the facility are included in the Consolidated Balance Sheets as accounts receivable. At March 31, 2023 and September 30, 2022, the outstanding amounts of accounts receivable transferred by Ashland were $ 150 million and $ 162 million, respectively, and there were zero borrowings (denominated in multiple currencies) under the facility in both periods. Available borrowing capacity and liquidity The borrowing capacity remaining under the 2022 Credit Agreement which included the $ 600 million Revolving Credit Facility was $ 582 million due to an outstanding balance of zero , as well as a reduction of $ 18 million for letters of credit outstanding as of March 31, 2023. Ashland's total borrowing capacity at March 31, 2023 was $ 690 million, which included $ 108 million of available capacity from the foreign 2018 Accounts Receivable Securitization Facility. Additionally, Ashland had zero available liquidity under its current U.S. Accounts Receivable Sales Program as of March 31, 2023. Covenants related to current Ashland debt agreements Ashland's debt contains usual and customary representations, warranties and affirmative and negative covenants, including financial covenants for leverage and interest coverage ratios, limitations on liens, additional subsidiary indebtedness, restrictions on subsidiary distributions, investments, mergers, sale of assets and restricted payments and other customary limitations. As of March 31, 2023, Ashland is in compliance with all debt agreement covenant restrictions. The maximum consolidated net leverage ratio permitted under Ashland's current credit agreement (the 2022 Credit Agreement) is 4.0 . At March 31, 2023 , Ashland’s calculation of the consolidated net leverage ratio was 1.6 . The minimum required consolidated interest coverage ratio under the 2022 Credit Agreement during its entire duration is 3.0 . At March 31, 2023 , Ashland’s calculation of the interest coverage ratio was 10.6 . |
Leasing Arrangements
Leasing Arrangements | 6 Months Ended |
Mar. 31, 2023 | |
Leases [Abstract] | |
Leasing Arrangements | NOTE I – LEASING ARRANGEMENTS The components of lease cost recognized within the Statements of Consolidated Comprehensive Income (Loss) were as follows : Three months ended Six months ended March 31 March 31 (In millions) Location 2023 2022 2023 2022 Lease cost: Operating lease cost Selling, General & Administrative $ 3 $ 3 $ 6 $ 6 Operating lease cost Cost of Sales 4 4 8 8 Variable lease cost Selling, General & Administrative 1 1 2 2 Variable lease cost Cost of Sales 1 1 2 2 Short-term leases Cost of Sales 1 1 1 1 Total lease cost $ 10 $ 10 $ 19 $ 19 Right-of-use assets exchanged for new operating lease obligations were $ 20 million and $ 3 million for the three months ended March 31, 2023 and 2022, respectively, and $ 23 and $ 4 million for the six months ended March 31, 2023 and 2022. The following table provides cash paid for amounts included in the measurement of operating lease liabilities: Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Operating cash flows from operating leases $ 6 $ 7 $ 13 $ 14 |
Income Taxes
Income Taxes | 6 Months Ended |
Mar. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | NOTE J – INCOME TAXES Current fiscal year Ashland’s effective tax rate in any interim period is subject to adjustments related to discrete items and the mix of domestic and foreign operating results. The overall effective tax rate was a benefit 1 % and 5 % for the three and six months ended March 31, 2023. The current quarter tax rate was impacted by jurisdictional income mix, as well as net $ 20 million from favorable tax discrete items primarily related to changes in uncertain tax positions. The current six month tax rate was impacted by jurisdictional income mix, as well as net $ 23 million from favorable tax discrete items primarily related to changes in uncertain tax positions resulting primarily from a combination of state expirations and audit settlements. Prior fiscal year The overall effective tax rate was 34 % and 25 % for the three and six months ended March 31, 2022 . The quarter tax rate was impacted by jurisdictional income mix, as well as $ 7 million from net unfavorable tax discrete items primarily related to restructuring and separation activity partially offset by a favorable valuation allowance adjustment for certain foreign tax credits. The six months tax rate was impacted by jurisdictional income mix as well as $ 5 million from net unfavorable tax discrete items primarily related to restructuring and separation activity partially offset by a favorable valuation adjustment for certain foreign tax credits and adjustments to uncertain positions. Unrecognized tax benefits Changes in unrecognized tax benefits are summarized as follows for the six months ended March 31, 2023. (In millions) Balance at October 1, 2022 $ 84 Increases related to positions taken in prior years 1 Decreases related to positions taken in prior years ( 27 ) Increases related to positions taken in the current year 2 Lapse of statute of limitations ( 1 ) Balance at March 31, 2023 $ 59 From a combination of statute expirations and audit settlements in the next twelve months, Ashland expects a decrease in the amount accrued for uncertain tax positions of between $ 3 million and $ 5 million. It is reasonably possible that there could be other material changes to the amount of uncertain tax positions due to activities of the taxing authorities, settlement of audit issues or the reassessment of existing uncertain tax positions; however, Ashland is not able to estimate the impact of these items at this time. |
Employee Benefit Plans
Employee Benefit Plans | 6 Months Ended |
Mar. 31, 2023 | |
Retirement Benefits [Abstract] | |
Employee Benefit Plans | NOTE K - EMPLOYEE BENEFIT PLANS Plan contributions For the six months ended March 31, 2023 , Ashland contributed $ 3 million to its non-U.S. pension plans and zero to its U.S. pension plans. Ashland expects to make additional contributions of approximately $ 3 million to its U.S. pension plans and expects to make additional contributions of approximately $ 1 million to its non-U.S. pension plans during the remainder of fiscal 2023. Plan Remeasurements Following the completion of the sale of its Performance Adhesives business segment on February 28, 2022, the post-retirement benefits for approximately 40 employees transferred to Arkema, all of whom participated in a non-contributory defined benefit plan in the U.S., were frozen. This resulted in a significant decrease in total expected future years of service within the plan and required Ashland to remeasure the plan as February 28, 2022. As a result, Ashland recorded a $ 1 million actuarial gain within the other net periodic benefits income caption of the Statements of Consolidated Comprehensive Income (Loss) for the three and six months ended March 31, 2022. Components of net periodic benefit costs (income) The following table details the components of pension and other postretirement benefit costs for continuing operations. Pension benefits Other postretirement (In millions) 2023 2022 2023 2022 Three months ended March 31 Service cost $ 1 $ 1 $ — $ — Interest cost 3 1 1 1 Expected return on plan assets ( 2 ) ( 2 ) — — Actuarial (gain) — ( 1 ) — — Total net periodic benefit costs $ 2 $ ( 1 ) $ 1 $ 1 Six months ended March 31 Service cost $ 2 $ 2 $ — $ — Interest cost 6 3 1 1 Expected return on plan assets ( 4 ) ( 4 ) — — Actuarial (gain) — ( 1 ) — — Total net periodic benefit costs $ 4 $ — $ 1 $ 1 For segment reporting purposes, service cost is proportionately allocated to each segment, excluding the Unallocated and other segment, and is recorded within the selling, general and administrative expense and cost of sales captions on the Statements of Consolidated Comprehensive Income (Loss). All other components are recorded within the other net periodic benefit loss caption on the Statements of Consolidated Comprehensive Income (Loss), which netted to a loss of $ 2 million and $ 3 million for the three and six months ended March 31, 2023 , respectively, and a gain of $ 1 million for the three and six months ended March 31, 2022 . |
Litigation, Claims and Continge
Litigation, Claims and Contingencies | 6 Months Ended |
Mar. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Litigation, Claims and Contingencies | NOTE L – LITIGATION, CLAIMS AND CONTINGENCIES Asbestos litigation Ashland is subject to liabilities from claims alleging personal injury caused by exposure to asbestos. Such claims result from indemnification obligations undertaken in 1990 in connection with the sale of Riley Stoker Corporation (Riley) and the acquisition of Hercules in November 2008. Although Riley, a former subsidiary, was neither a producer nor a manufacturer of asbestos, its industrial boilers contained some asbestos-containing components provided by other companies. Hercules, an indirect wholly-owned subsidiary of Ashland, has liabilities from claims alleging personal injury caused by exposure to asbestos. Such claims typically arise from alleged exposure to asbestos fibers from resin encapsulated pipe and tank products sold by one of Hercules’ former subsidiaries to a limited industrial market. To assist in developing and annually updating independent reserve estimates for future asbestos claims and related costs given various assumptions for Ashland and Hercules asbestos claims, Ashland retained third party actuarial experts Gnarus. The methodology used by Gnarus to project future asbestos costs is based largely on recent experience, including claim-filing and settlement rates, disease mix, open claims and litigation defense. The claim experience of Ashland and Hercules are separately compared to the results of previously conducted third party epidemiological studies estimating the number of people likely to develop asbestos-related diseases. Those studies were undertaken in connection with national analyses of the population expected to have been exposed to asbestos. Using that information, Gnarus estimates a range of the number of future claims that may be filed, as well as the related costs that may be incurred in resolving those claims. Changes in asbestos-related liabilities and receivables are recorded on an after-tax basis within the discontinued operations caption in the Statements of Consolidated Comprehensive Income (Loss). Ashland asbestos-related litigation The claims alleging personal injury caused by exposure to asbestos asserted against Ashland result primarily from indemnification obligations undertaken in 1990 in connection with the sale of Riley. The amount and timing of settlements and number of open claims can fluctuate from period to period. A summary of Ashland asbestos claims activity, excluding Hercules claims, follows. Six months ended March 31 Years ended September 30 (In thousands) 2023 2022 2022 2021 2020 Open claims - beginning of year 44 46 46 49 53 New claims filed 1 1 2 2 2 Claims settled — ( 1 ) ( 1 ) ( 1 ) ( 1 ) Claims dismissed ( 2 ) ( 1 ) ( 3 ) ( 4 ) ( 5 ) Open claims - end of period 43 45 44 46 49 Ashland asbestos-related liability From the range of estimates, Ashland records the amount it believes to be the best estimate of future payments for litigation defense and claim settlement costs. Ashland reviews this estimate and related assumptions quarterly and annually updates the results of a non-inflated, non-discounted approximate 40-year model developed with the assistance of Gnarus. During the most recent update completed during 2022, it was determined that the liability for Ashland asbestos-related claims should be increased by $ 16 million. Total reserves for asbestos claims were $ 285 million at March 31, 2023 compared to $ 305 million at September 30, 2022. A progression of activity in the asbestos reserve is presented in the following table. Six months ended March 31 Years ended September 30 (In millions) 2023 2022 2022 2021 2020 Asbestos reserve - beginning of year $ 305 $ 320 $ 320 $ 335 $ 352 Reserve adjustment — — 16 12 13 Amounts paid ( 20 ) ( 19 ) ( 31 ) ( 27 ) ( 30 ) Asbestos reserve - end of period (a) $ 285 $ 301 $ 305 $ 320 $ 335 (a) Included $ 29 million classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . Ashland asbestos-related receivables Ashland has insurance coverage for certain litigation defense and claim settlement costs incurred in connection with its asbestos claims, and coverage-in-place agreements exist with the insurance companies that provide substantially all of the coverage that will be accessed. For the Ashland asbestos-related obligations, Ashland has estimated the value of probable insurance recoveries associated with its asbestos reserve based on management’s interpretations and estimates surrounding the available or applicable insurance coverage, including an assumption that all solvent insurance carriers remain solvent. Substantially all of the estimated receivables from insurance companies are expected to be due from domestic insurers, all of which are solvent. At March 31, 2023, Ashland’s receivable for recoveries of litigation defense and claim settlement costs from insurers amounted to $ 96 million (excluding the Hercules receivable for asbestos claims discussed below) compared to $ 101 million at September 30, 2022 . During fiscal year 2022, the annual update of the model used for purposes of valuing the asbestos reserve and its impact on valuation of future recoveries from insurers was completed. This model update resulted in a $ 7 million increase in the receivable for probable insurance recoveries. A progression of activity in the Ashland insurance receivable is presented in the following table. Six months ended March 31 Years ended September 30 (In millions) 2023 2022 2022 2021 2020 Insurance receivable - beginning of year $ 101 $ 100 $ 100 $ 103 $ 123 Receivable adjustment (a) — — 7 6 1 Insurance settlement — — — — ( 10 ) Amounts collected ( 5 ) ( 2 ) ( 6 ) ( 9 ) ( 11 ) Insurance receivable - end of period (b) $ 96 $ 98 $ 101 $ 100 $ 103 (a) 2021 includes a $ 2 million reserve adjustment related to allowances for credit losses as a result of Ashland's adoption of the new credit measurement standard. The total allowance for credit losses was $ 2 million as of March 31, 2023 and September 30, 2022. (b) Includes $ 12 million classified in accounts receivable on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . Hercules asbestos-related litigation Hercules has liabilities from claims alleging personal injury caused by exposure to asbestos. Such claims typically arise from alleged exposure to asbestos fibers from resin encapsulated pipe and tank products which were sold by one of Hercules’ former subsidiaries to a limited industrial market. The amount and timing of settlements and number of open claims can fluctuate from period to period. A summary of Hercules’ asbestos claims activity follows. Six months ended March 31 Years ended September 30 (In thousands) 2023 2022 2022 2021 2020 Open claims - beginning of year 11 12 12 12 13 New claims filed 1 1 1 1 1 Claims dismissed — ( 1 ) ( 2 ) ( 1 ) ( 2 ) Open claims - end of period 12 12 11 12 12 Hercules asbestos-related liability From the range of estimates, Ashland records the amount it believes to be the best estimate of future payments for litigation defense and claim settlement costs. Ashland reviews this estimate, and related assumptions quarterly and annually updates the results of a non-inflated, non-discounted approximate 40-year model developed with the assistance of Gnarus. As a result of the most recent annual update of this estimate, completed during fiscal year 2022, it was determined that the liability for Hercules asbestos-related claims should be increased by $ 15 million. Total reserves for asbestos claims were $ 205 million at March 31, 2023 compared to $ 213 million at September 30, 2022. A progression of activity in the asbestos reserve is presented in the following table. Six months ended March 31 Years ended September 30 (In millions) 2023 2022 2022 2021 2020 Asbestos reserve - beginning of year $ 213 $ 217 $ 217 $ 229 $ 252 Reserve adjustments — — 15 8 ( 3 ) Amounts paid ( 8 ) ( 10 ) ( 19 ) ( 20 ) ( 20 ) Asbestos reserve - end of period (a) $ 205 $ 207 $ 213 $ 217 $ 229 (a) Included $ 18 million classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . Hercules asbestos-related receivables For the Hercules asbestos-related obligations, certain reimbursement obligations pursuant to coverage-in-place agreements with insurance carriers exist. As a result, any increases in the asbestos reserve have been partially offset by probable insurance recoveries. Ashland has estimated the value of probable insurance recoveries associated with its asbestos reserve based on management’s interpretations and estimates surrounding the available or applicable insurance coverage, including an assumption that all solvent insurance carriers remain solvent. The estimated receivable consists exclusively of solvent domestic insurers. As of March 31, 2023, Ashland’s receivable for recoveries of litigation defense and claims costs from insurers with respect to Hercules amounted to $ 51 million compared to $ 52 million at September 30, 2022 . During fiscal year 2022, the annual update of the model used for purposes of valuing the asbestos reserve and its impact on valuation of future recoveries from insurers was completed. This model update resulted in an increase of $ 7 million in the receivable for probable insurance recoveries. A progression of activity in the Hercules insurance receivable is presented in the following table. Six months ended March 31 Years ended September 30 (In millions) 2023 2022 2022 2021 2020 Insurance receivable - beginning of year $ 52 $ 47 $ 47 $ 47 $ 49 Receivable adjustment (a) — — 7 1 ( 2 ) Amounts collected ( 1 ) ( 1 ) ( 2 ) ( 1 ) — Insurance receivable - end of period (b) $ 51 $ 46 $ 52 $ 47 $ 47 (a) 2021 includes a $ 1 million reserve adjustment related to allowances for credit losses as a result of Ashland's adoption of the new credit measurement standard. The total allowance for credit losses was $ 1 million as of March 31, 2023 and September 30, 2022 . (b) Includes $ 2 million and $ 3 million classified in accounts receivable on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 , respectively. Asbestos litigation cost projection Projecting future asbestos costs is subject to numerous variables that are difficult to predict. In addition to the uncertainties surrounding the number of claims that might be received, other variables include the type and severity of the disease alleged by each claimant and the related costs incurred in resolving those claims, mortality rates, dismissal rates, uncertainties surrounding the litigation process from jurisdiction to jurisdiction and from case to case. Furthermore, any predictions with respect to these variables are subject to even greater uncertainty as the projection period lengthens. In light of these inherent uncertainties, Ashland believes that the asbestos reserves for Ashland and Hercules represent the best estimate within a range of possible outcomes. As a part of the process to develop these estimates of future asbestos costs, a range of long-term cost models was developed. These models are based on national studies that predict the number of people likely to develop asbestos-related diseases and are heavily influenced by assumptions regarding long-term inflation rates for indemnity payments and legal defense costs, as well as other variables mentioned previously. Ashland has currently estimated in various models ranging from approximately 40 year periods that it is reasonably possible that total future litigation defense and claim settlement costs on an inflated and undiscounted basis could range as high as approximately $ 456 million for the Ashland asbestos-related litigation (current reserve of $ 285 million) and approximately $ 317 million for the Hercules asbestos-related litigation (current reserve of $ 205 million), depending on the combination of assumptions selected in the various models. While the timeframe used in Ashland’s models for projecting asbestos liabilities generally decreases over time based on the expected lifetime of the liabilities, these models have been consistently applied between all periods presented. If actual experience is worse than projected, relative to the number of claims filed, the severity of alleged disease associated with those claims or costs incurred to resolve those claims, or actuarial refinement or improvements to the assumptions used within these models are initiated, Ashland may need to further increase the estimates of the costs associated with asbestos claims and these increases could be material over time. Environmental remediation and asset retirement obligations Ashland is subject to various federal, state and local environmental laws and regulations that require environmental assessment or remediation efforts (collectively environmental remediation) at multiple locations. At March 31, 2023 , such locations included 58 sites where Ashland has been identified as a potentially responsible party under Superfund or similar state laws, 108 current and former operating facilities and about 1225 service station properties, of which 17 are being actively remediated. Ashland’s reserves for environmental remediation and related environmental litigation amounted to $ 193 million at March 31, 2023 compared to $ 211 million at September 30, 2022 , of which $ 144 million at March 31, 2023 and $ 157 million at September 30, 2022 were classified in other noncurrent liabilities on the Condensed Consolidated Balance Sheets. The remaining reserves were classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets. The following table provides a reconciliation of the changes in the environmental remediation reserves during the six months ended March 31, 2023 and 2022. Six months ended March 31 (In millions) 2023 2022 Reserve - beginning of period $ 211 $ 207 Disbursements ( 29 ) ( 30 ) Revised obligation estimates and accretion 11 15 Reserve - end of period $ 193 $ 192 The total reserves for environmental remediation reflect Ashland’s estimates of the most likely costs that will be incurred over an extended period to remediate identified conditions for which the costs are reasonably estimable, without regard to any third-party recoveries. Engineering studies, historical experience and other factors are used to identify and evaluate remediation alternatives and their related costs in determining the estimated reserves for environmental remediation. Ashland continues to discount certain environmental sites and regularly adjusts its reserves as environmental remediation continues. Ashland has estimated the value of its probable insurance recoveries associated with its environmental reserve based on management’s interpretations and estimates surrounding the available or applicable insurance coverage. At March 31, 2023 and September 30, 2022 , Ashland’s recorded receivable for these probable insurance recoveries was $ 19 million and $ 21 million, of which $ 16 million and $ 17 million at March 31, 2023 and September 30, 2022 were classified in other noncurrent assets on the Condensed Consolidated Balance Sheets. Components of environmental remediation expense included within the selling, general and administrative expense caption of the Statements of Consolidated Comprehensive Income (Loss) are presented in the following table for the three and six ended March 31, 2023 and 2022. Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Environmental expense $ 3 $ 12 $ 11 $ 15 Legal expense 1 1 2 2 Total expense 4 13 13 17 Insurance receivable — ( 3 ) — ( 3 ) Total expense, net of receivable activity (a) $ 4 $ 10 $ 13 $ 14 (a) Net expense of zero and $ 1 million for the three and six months ended March 31, 2023 , respectively, and $ 1 million and $ 2 million for the three and six months ended March 31, 2022, respectively, relates to divested businesses which qualified for treatment as discontinued operations for which certain environmental liabilities were retained by Ashland. These amounts are classified within the income (loss) from discontinued operations caption of the Statements of Consolidated Comprehensive Income (loss). Environmental remediation reserves are subject to uncertainties that affect Ashland’s ability to estimate its share of the costs. Such uncertainties involve the nature and extent of contamination at each site and the extent of required cleanup efforts under existing environmental regulations. Although it is not possible to predict with certainty the ultimate costs of environmental remediation, Ashland currently estimates that the upper end of the reasonably possible range of future costs for identified sites could be as high as approximately $ 445 million. The largest reserve for any site is 14 % of the remediation reserve. Other legal proceedings and claims In addition to the matters described above, there are other various claims, lawsuits and administrative proceedings pending or threatened against Ashland and its current and former subsidiaries. Such actions are with respect to commercial matters, product liability, toxic tort liability, and other environmental matters, which seek remedies or damages, some of which are for substantial amounts. While Ashland cannot predict with certainty the outcome of such actions, it believes that adequate reserves have been recorded and losses already recognized with respect to such actions were immaterial as of March 31, 2023. There is a reasonable possibility that a loss exceeding amounts already recognized may be incurred related to these actions; however, Ashland believes that such potential losses were immaterial as of March 31, 2023 . |
Earnings Per Share
Earnings Per Share | 6 Months Ended |
Mar. 31, 2023 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | NOTE M – EARNINGS PER SHARE The following is the computation of basic and diluted earnings per share (EPS) from continuing operations attributable to Ashland. Stock appreciation rights (SARs), stock options and warrants available to purchase shares outstanding for each reporting period whose grant price was greater than the average market price of Ashland Common Stock for each applicable period were not included in the computation of income from continuing operations per diluted share because the effect of these instruments would be antidilutive . The total number of these shares outstanding was approximately 1 million at March 31, 2023 and 2022 , respectively. The majority of these shares are for warrants with a strike price of $ 128.66 . Earnings per share is reported under the treasury stock method. Three months ended Six months ended March 31 March 31 (In millions, except per share data) 2023 2022 2023 2022 Numerator Numerator for basic and diluted EPS - $ 92 $ 38 $ 134 $ 70 Denominator Denominator for basic EPS - Weighted- 54 56 54 57 Share based awards convertible to common shares 1 1 1 1 Denominator for diluted EPS - Adjusted weighted- 55 57 55 58 EPS from continuing operations Basic $ 1.71 $ 0.67 $ 2.47 $ 1.22 Diluted 1.68 0.66 2.43 1.20 |
Equity Items
Equity Items | 6 Months Ended |
Mar. 31, 2023 | |
Equity [Abstract] | |
Equity Items | NOTE N – EQUITY ITEMS Stock repurchase program agreements During March 2023, under the 2022 stock repurchase program, Ashland initiated a Rule 10b5-1 trading plan agreement to repurchase up to $ 100 million of its outstanding shares. The program was completed during April 2023, when Ashland paid a total of $ 100 million and received a delivery of 1.0 million shares of common stock. As of March 31, 2023, Ashland purchased a total of $ 52 million (of which $ 42 million was cash settled and $ 10 million was accrued within the accrued expenses and other liabilities caption for authorized and executed share repurchases pending settlement as of period end) and receive a delivery of 0.5 million shares of common stock. During February 2023, under the 2022 stock repurchase program, Ashland initiated a Rule 10b5-1 trading plan agreement to repurchase up to $ 100 million of its outstanding shares. The program was completed during February 2023, when Ashland paid a total of $ 100 million and received a delivery of 1.0 million shares of common stock. On March 1, 2022, under the 2018 stock repurchase program, Ashland entered into an agreement to repurchase an aggregate amount of $ 200 million of Ashland common stock using open-market purchases under rule 10b-18. As of March 31, 2022, Ashland paid $ 155 million and received 1.7 million shares of common stock under the agreement. Stockholder dividends Dividends of 33.5 cents per share were paid in the first and second quarters of fiscal 2023 and 30 cents per share were paid in the first and second quarters of fiscal 2022. Accumulated other comprehensive income (loss) Components of other comprehensive income (loss) recorded in the Statements of Consolidated Comprehensive Income (Loss) are presented below, before tax and net of tax effects. 2023 2022 (In millions) Before Tax Net of Before Tax Net of Three months ended March 31 Other comprehensive income (loss) Unrealized translation gain (loss) $ 27 $ — $ 27 $ ( 5 ) $ — $ ( 5 ) Unrealized gain (loss) on commodity hedges ( 4 ) 1 ( 3 ) 6 ( 1 ) 5 Total other comprehensive income (loss) $ 23 $ 1 $ 24 $ 1 $ ( 1 ) $ — Six months ended March 31 Other comprehensive income (loss) Unrealized translation gain (loss) $ 110 $ ( 1 ) $ 109 $ ( 22 ) $ 1 $ ( 21 ) Unrealized gain (loss) on commodity hedges ( 9 ) 2 ( 7 ) 1 — 1 Total other comprehensive income (loss) $ 101 $ 1 $ 102 $ ( 21 ) $ 1 $ ( 20 ) Summary of stockholders’ equity A reconciliation of changes in stockholders’ equity are as follows: Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Common stock and paid in capital Balance, beginning of period $ 134 $ 328 $ 136 $ 328 Compensation expense and common shares issued (a) 4 4 2 4 Common shares purchased under repurchase program (b) (c) ( 138 ) ( 155 ) ( 138 ) ( 155 ) Balance, end of period — 177 — 177 Retained earnings Balance, beginning of period 3,675 2,827 3,653 2,796 Net income 91 786 132 834 Regular dividends ( 18 ) ( 17 ) ( 36 ) ( 34 ) Common shares purchased under repurchase program (b) ( 15 ) — ( 15 ) — Other 1 — — — Balance, end of period 3,734 3,596 3,734 3,596 Accumulated other comprehensive income (loss) Balance, beginning of period ( 491 ) ( 392 ) ( 569 ) ( 372 ) Unrealized translation gain (loss) 27 ( 5 ) 109 ( 21 ) Unrealized gain (loss) on commodity hedges ( 3 ) 5 ( 7 ) 1 Balance, end of period ( 467 ) ( 392 ) ( 467 ) ( 392 ) Total stockholders' equity $ 3,267 $ 3,381 $ 3,267 $ 3,381 Cash dividends declared per common share $ 0.335 $ 0.300 $ 0.670 $ 0.600 (a) Common shares issued were 16,937 shares and 13,935 shares for the three months ended March 31, 2023 and 2022 , respectively, and 144,514 shares and 108,650 shares for the six months ended March 31, 2023 and 2022 , respectively. (b) Common shares repurchased were 1,488,251 shares for the three and six months ended March 31, 2023, and 2,403,380 shares for the three and six months ended March 31, 2022. (c) Includes $ 1 million in excise tax on stock repurchases for the three and six months ended March 31, 2023. |
Stock Incentive Plans
Stock Incentive Plans | 6 Months Ended |
Mar. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Stock Incentive Plans | NOTE O – STOCK INCENTIVE PLANS The components of Ashland’s pre-tax stock-based compensation expense included in continuing operations are as follows: Three months ended Six months ended March 31 March 31 (In millions) 2023 (a) 2022 (b) 2023 (a) 2022 (b) Nonvested stock awards $ 4 $ 2 $ 7 $ 6 Performance share awards 2 3 7 5 $ 6 $ 5 $ 14 $ 11 (a) Included $ 1 million and $ 2 million of expense related to cash-settled nonvested restricted stock awards during the three and six months ended March 31, 2023 . (b) Included zero and $ 2 million of expense related to cash-settled nonvested restricted stock awards during the three and six months ended March 31, 2022 . |
Revenue
Revenue | 6 Months Ended |
Mar. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | NOTE P – REVENUE Disaggregation of revenue Ashland disaggregates its revenue by segment and geographical region as Ashland believes these categories best depict how management reviews the financial performance of its operations. Ashland includes only U.S. and Canada in its North America designation and includes Europe, the Middle East and Africa in its Europe designation. See the following tables for details. See Note Q for additional information. Sales by geography Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Life Sciences North America $ 61 $ 62 $ 109 $ 115 Europe 87 66 160 121 Asia Pacific 62 52 122 98 Latin America & other 30 24 56 40 $ 240 $ 204 $ 447 $ 374 Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Personal Care North America $ 48 $ 55 $ 90 $ 96 Europe 69 69 120 125 Asia Pacific 28 30 56 62 Latin America & other 22 18 39 35 $ 167 $ 172 $ 305 $ 318 Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Specialty Additives North America $ 52 $ 61 $ 105 $ 114 Europe 61 69 109 125 Asia Pacific 39 45 74 85 Latin America & other 9 7 16 14 $ 161 $ 182 $ 304 $ 338 Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Intermediates North America $ 36 $ 43 $ 70 $ 74 Europe 7 10 16 19 Asia Pacific 6 11 14 21 Latin America & other 2 2 5 5 $ 51 $ 66 $ 105 $ 119 Trade receivables Trade receivables are defined as receivables arising from contracts with customers and are recorded within the accounts receivable caption within the Condensed Consolidated Balance Sheets. Ashland’s trade receivables were $ 365 million and $ 369 million as of March 31, 2023 and September 30, 2022 , respectively. See Note H for additional information on Ashland’s program to sell certain receivables on a revolving basis to third party banks up to an aggregate purchase limit (U.S Accounts Receivable Sales Program). |
Reportable Segment Information
Reportable Segment Information | 6 Months Ended |
Mar. 31, 2023 | |
Segment Reporting [Abstract] | |
Reportable Segment Information | NOTE Q – REPORTABLE SEGMENT INFORMATION Ashland determines its reportable segments based on how operations are managed internally for the products and services sold to customers, including how the results are reviewed by the chief operating decision maker, which includes determining resource allocation methodologies used for reportable segments. Operating income and EBITDA are the primary measures of performance that are reviewed by the chief operating decision maker in assessing each reportable segment's financial performance. Ashland does not aggregate operating segments to arrive at these reportable segments. Reportable segment business descriptions Life Sciences is comprised of pharmaceuticals, nutrition, nutraceuticals, agricultural chemicals, diagnostic films (formerly known as advanced materials) and fine chemicals. Pharmaceutical solutions include controlled release polymers, disintegrants, film coatings, solubilizers, and tablet binders. Nutrition solutions include thickeners, stabilizers, emulsifiers and additives for enhancing mouthfeel, controlling moisture migration, reducing oil uptake and controlling color. Nutraceutical solutions include products for weight management, joint comfort, stomach and intestinal health, sports nutrition and general wellness, and provide custom formulation, toll processing and particle engineering solutions. Customers include pharmaceutical, food, beverage, nutraceuticals and supplements manufacturers, hospitals and radiologists and industrial manufacturers. Personal Care is comprised of biofunctionals, microbial protectants (preservatives), skin care, sun care, oral care, hair care and household. These businesses have a broad range of natural, nature-derived, biodegradable, and high-performance ingredients for customer-driven solutions to help protect, renew, moisturize and revitalize skin and hair, and provide solutions for toothpastes, mouth washes and rinses, denture cleaning and care for teeth. Household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers for household, industrial and institutional cleaning products. Customers include formulators at large multinational branded consumer products companies and smaller, independent boutique companies. Specialty Additives is comprised of rheology and performance-enhancing additives serving the architectural coatings, construction, energy, automotive and various industrial markets. Solutions include coatings additives for architectural paints, finishes and lacquers, cement and gypsum based dry mortars, ready-mixed joint compounds, synthetic plasters for commercial and residential construction, and specialty materials for industrial applications. Products include rheology modifiers (cellulosic and associative thickeners), foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, and environmental filters, ingredients that aid the manufacturing process of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals and alloys for welding. Products help improve desired functional outcomes through rheology modification and control, water retention, workability, adhesive strength, binding power, film formation, deposition and suspension and emulsification. Customers include global paint manufacturers, electronics and automotive manufacturers, textile mills, the construction industry, and welders. Intermediates is comprised of the production of 1,4 butanediol (BDO) and related derivatives, including n-methylpyrrolidone. These products are used as chemical intermediates in the production of engineering polymers and polyurethanes, and as specialty process solvents in a wide array of applications including electronics, pharmaceuticals, water filtration membranes and more. Butanediol is also supplied to Life Sciences, Personal Care, and Specialty Additives for use as a raw material. Unallocated and Other generally includes items such as certain significant company-wide restructuring activities, corporate governance costs and legacy costs or activities that relate to divested businesses that are no longer operated by Ashland. Reportable segment results Results of Ashland’s reportable segments are presented based on its management and internal accounting structure. The structure is specific to Ashland; therefore, the financial results of Ashland’s reportable segments are not necessarily comparable with similar information for other comparable companies. Ashland allocates all significant costs to its reportable segments except for certain significant company-wide restructuring activities, certain corporate governance costs and other costs or activities that relate to former businesses that Ashland no longer operates. The service cost component of pension and other postretirement benefits costs is allocated to each reportable segment on a ratable basis; while the remaining components of pension and other postretirement benefits costs are recorded within the other net periodic benefit loss caption on the Statements of Consolidated Comprehensive Income (Loss). Ashland refines its expense allocation methodologies to the reportable segments from time to time as internal accounting practices are improved, more refined information becomes available and the industry or market changes. Significant revisions to Ashland’s methodologies are adjusted for all segments on a retrospective basis. The following table presents various financial information for each reportable segment for the three and six months ended March 31, 2023 and 2022. Three months ended Six months ended March 31 March 31 (In millions - unaudited) 2023 2022 2023 2022 SALES Life Sciences $ 240 $ 204 $ 447 $ 374 Personal Care 167 172 305 318 Specialty Additives 161 182 304 338 Intermediates 51 66 105 119 Intersegment sales (a) ( 16 ) ( 20 ) ( 33 ) ( 34 ) $ 603 $ 604 $ 1,128 $ 1,115 OPERATING INCOME (LOSS) Life Sciences $ 58 $ 43 $ 92 $ 64 Personal Care 14 28 25 42 Specialty Additives 15 26 16 44 Intermediates 17 27 37 42 Unallocated and other ( 21 ) ( 24 ) ( 50 ) ( 50 ) $ 83 $ 100 $ 120 $ 142 DEPRECIATION EXPENSE Life Sciences $ 10 $ 8 $ 20 $ 16 Personal Care 10 9 20 18 Specialty Additives 14 17 28 33 Intermediates 3 3 6 7 $ 37 $ 37 $ 74 $ 74 AMORTIZATION EXPENSE Life Sciences $ 7 $ 7 $ 14 $ 14 Personal Care 11 12 22 24 Specialty Additives 5 5 9 9 Intermediates — — 1 — $ 23 $ 24 $ 46 $ 47 EBITDA (b) Life Sciences $ 75 $ 58 $ 126 $ 94 Personal Care 35 49 67 84 Specialty Additives 34 48 53 86 Intermediates 20 30 44 49 Unallocated and other ( 21 ) ( 24 ) ( 50 ) ( 50 ) $ 143 $ 161 $ 240 $ 263 March 31 September 30 (In millions - unaudited) 2023 2022 TOTAL ASSETS Life Sciences $ 1,964 $ 1,905 Personal Care 1,079 1,073 Specialty Additives 1,664 1,567 Intermediates 172 170 Unallocated and other 1,304 1,498 $ 6,183 $ 6,213 (a) Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost. (b) Excludes income (loss) from discontinued operations and other net periodic benefit loss (income). See the Statement of Consolidated Comprehensive Income (Loss) for applicable amounts excluded. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 6 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation | Basis of presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial reporting and Securities and Exchange Commission (SEC) regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. These statements omit certain information and footnote disclosures required for complete annual financial statements and, therefore, should be read in conjunction with the Ashland Inc. and consolidated subsidiaries (Ashland) Annual Report on Form 10-K for the fiscal year ended September 30, 2022. Results of operations for the period ended March 31, 2023 are not necessarily indicative of the expected results for the remaining quarters in the fiscal year. Ashland is comprised of the following reportable segments: Life Sciences, Personal Care, Specialty Additives and Intermediates. Unallocated and Other includes corporate governance activities and certain legacy matters. For additional information, see Note Q. |
Use of Estimates, Risks and Uncertainties | Use of estimates, risks and uncertainties The preparation of Ashland’s Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales and expenses, and the disclosures of contingent assets and liabilities. Significant items that are subject to such estimates and assumptions include, but are not limited to, environmental remediation, asbestos litigation, the accounting for goodwill and other intangible assets, and income taxes. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ significantly from the estimates under different assumptions or conditions. Ashland’s results are affected by domestic and international economic, political, legislative, regulatory and legal actions. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, government fiscal policies and changes in the prices of certain key raw materials, can have a significant effect on operations. While Ashland maintains reserves for anticipated liabilities and carries various levels of insurance, Ashland could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings relating to asbestos, environmental remediation or other matters. |
New Accounting Pronouncements | New accounting pronouncements A description of new U.S. GAAP accounting standards issued or adopted during the current year is required in interim financial reporting. A detailed listing of new accounting standards relevant to Ashland is included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2022 . There were no new standards that were either issued or adopted in the current fiscal year that will have a material impact on Ashland's consolidated financial statements. |
Fair Value of Financial Instruments Policy | Level 1 – Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3 – Unobservable inputs for the asset or liability for which there is little, if any, market activity at the measurement date. Unobservable inputs reflect Ashland’s own assumptions about what market participants would use to price the asset or liability. The inputs are developed based on the best information available in the circumstances, which might include Ashland’s own financial data such as internally developed pricing models, discounted cash flow methodologies, as well as instruments for which the fair value determination requires significant management judgment. For assets that are measured using quoted prices in active markets (Level 1), the total fair value is the published market price per unit multiplied by the number of units held without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs (Level 2) are primarily valued by reference to quoted prices of similar assets or liabilities in active markets, adjusted for any terms specific to that asset or liability. For all other assets and liabilities for which unobservable inputs are used (Level 3), fair value is derived using fair value models, such as a discounted cash flow model or other standard pricing models that Ashland deems reasonable. |
Inventories | Inventories are carried at the lower of cost or net realizable value. Inventories are stated at cost using the weighted-average cost method. This method values inventories using average costs for raw materials and most recent production costs for labor and overhead. |
Goodwill and Intangible Assets, Goodwill | Ashland tests goodwill and other indefinite-lived intangible assets for impairment annually as of July 1 and when events and circumstances indicate an impairment may have occurred. N o indicators of impairment were identified in the three and six months ended March 31, 2023 . |
Finite-Lived Intangible Asset | Intangible assets principally consist of trademarks and trade names, intellectual property and customer and supplier relationships. Intangible assets classified as finite are amortized on a straight-line basis over their estimated useful lives. The cost of trademarks and trade names is amortized principally over 3 to 20 years , intellectual property over 3 to 20 years , and customer and supplier relationships over 10 to 24 years . |
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived | Ashland annually reviews, as of July 1, indefinite-lived intangible assets for possible impairment or whenever events or changes in circumstances indicate that carrying amounts may not be recoverable. No indicators of impairment were identified in the three and six months ended March 31, 2023 . |
Commitments and Contingencies Policy | Ashland is subject to liabilities from claims alleging personal injury caused by exposure to asbestos. Such claims result from indemnification obligations undertaken in 1990 in connection with the sale of Riley Stoker Corporation (Riley) and the acquisition of Hercules in November 2008. Although Riley, a former subsidiary, was neither a producer nor a manufacturer of asbestos, its industrial boilers contained some asbestos-containing components provided by other companies. Hercules, an indirect wholly-owned subsidiary of Ashland, has liabilities from claims alleging personal injury caused by exposure to asbestos. Such claims typically arise from alleged exposure to asbestos fibers from resin encapsulated pipe and tank products sold by one of Hercules’ former subsidiaries to a limited industrial market. To assist in developing and annually updating independent reserve estimates for future asbestos claims and related costs given various assumptions for Ashland and Hercules asbestos claims, Ashland retained third party actuarial experts Gnarus. The methodology used by Gnarus to project future asbestos costs is based largely on recent experience, including claim-filing and settlement rates, disease mix, open claims and litigation defense. The claim experience of Ashland and Hercules are separately compared to the results of previously conducted third party epidemiological studies estimating the number of people likely to develop asbestos-related diseases. Those studies were undertaken in connection with national analyses of the population expected to have been exposed to asbestos. Using that information, Gnarus estimates a range of the number of future claims that may be filed, as well as the related costs that may be incurred in resolving those claims. Changes in asbestos-related liabilities and receivables are recorded on an after-tax basis within the discontinued operations caption in the Statements of Consolidated Comprehensive Income (Loss). |
Environmental Cost Policy | The total reserves for environmental remediation reflect Ashland’s estimates of the most likely costs that will be incurred over an extended period to remediate identified conditions for which the costs are reasonably estimable, without regard to any third-party recoveries. Engineering studies, historical experience and other factors are used to identify and evaluate remediation alternatives and their related costs in determining the estimated reserves for environmental remediation. Ashland continues to discount certain environmental sites and regularly adjusts its reserves as environmental remediation continues. Ashland has estimated the value of its probable insurance recoveries associated with its environmental reserve based on management’s interpretations and estimates surrounding the available or applicable insurance coverage. At March 31, 2023 and September 30, 2022 , Ashland’s recorded receivable for these probable insurance recoveries was $ 19 million and $ 21 million, of which $ 16 million and $ 17 million at March 31, 2023 and September 30, 2022 were classified in other noncurrent assets on the Condensed Consolidated Balance Sheets. |
Earnings Per Share | . The total number of these shares outstanding was approximately 1 million at March 31, 2023 and 2022 , respectively. The majority of these shares are for warrants with a strike price of $ 128.66 . Earnings per share is reported under the treasury stock method. |
Segment Reporting | Ashland determines its reportable segments based on how operations are managed internally for the products and services sold to customers, including how the results are reviewed by the chief operating decision maker, which includes determining resource allocation methodologies used for reportable segments. Operating income and EBITDA are the primary measures of performance that are reviewed by the chief operating decision maker in assessing each reportable segment's financial performance. Ashland does not aggregate operating segments to arrive at these reportable segments. |
Discontinued Operations (Tables
Discontinued Operations (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Components of Amounts in the Statements of Consolidated Income (Loss) Related To Discontinued Operations | Components of amounts reflected in the Statements of Consolidated Comprehensive Income (Loss) related to discontinued operations are presented in the following table for the three and six months ended March 31, 2023 and 2022. Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Income (loss) from discontinued operations (net of tax) Performance Adhesives $ — $ 17 $ — $ 34 Composites/Marl facility ( 1 ) — ( 1 ) — Distribution — ( 1 ) ( 1 ) ( 2 ) Gain on disposal of discontinued operations (net of tax) Performance Adhesives — 732 — 732 $ ( 1 ) $ 748 $ ( 2 ) $ 764 |
Performance Adhesives [Member] | |
Components of Amounts in the Statements of Consolidated Income (Loss) Related To Discontinued Operations | The following table presents a reconciliation of the captions within Ashland's Statements of Consolidated Comprehensive Income (Loss) for the income (loss) from discontinued operations attributable to Performance Adhesives for the three and six months ended March 31, 2022. This disclosure was not applicable for the three and six months ended March 31, 2023 as a result of the sale in fiscal 2022. Three months ended Six months ended March 31 March 31 (In millions) 2022 2022 Income (loss) from discontinued operations attributable to Performance Adhesives Sales $ 75 $ 171 Cost of sales ( 56 ) ( 122 ) Selling, general and administrative expense ( 6 ) ( 11 ) Research and development expense ( 1 ) ( 3 ) Pretax income of discontinued operations 12 35 Income tax (expense) benefit 5 ( 1 ) Income from discontinued operations $ 17 $ 34 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] | |
Summary of Financial Instruments Subject to Recurring Fair Value Measurements | The following table summarizes financial instruments subject to recurring fair value measurements as of March 31, 2023. Carrying Total Quoted prices Significant Significant (In millions) value value Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 399 $ 399 $ 399 $ — $ — Restricted investments (a) (b) 410 410 410 — — Investment of captive insurance company (c) 4 4 4 — — Foreign currency derivatives (d) 2 2 — 2 — Total assets at fair value $ 815 $ 815 $ 813 $ 2 $ — Liabilities Foreign currency derivatives (e) $ 2 $ 2 $ — $ 2 $ — Commodity derivatives (e) 6 6 — 6 — Total liabilities at fair value $ 8 $ 8 $ — $ 8 $ — (a) Included in restricted investments and $ 61 million within other current assets in the Condensed Consolidated Balance Sheets . (b) Includes $ 267 million related to the Asbestos trust and $ 143 million related to the Environmental trust . (c) Included in other noncurrent assets in the Condensed Consolidated Balance Sheets . (d) Included in accounts receivable in the Condensed Consolidated Balance Sheets . (e) Included in accrued expenses and other liabilities in the Condensed Consolidated Balance Sheets. The following table summarizes financial asset instruments subject to recurring fair value measurements as of September 30, 2022. Carrying Total Quoted prices Significant Significant (In millions) value value Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 646 $ 646 $ 646 $ — $ — Restricted investments (a) (b) 374 374 374 — — Investment of captive insurance company (c) 9 9 9 — — Foreign currency derivatives (d) 1 1 — 1 — Commodity derivatives (d) 4 4 — 4 — Total assets at fair value $ 1,034 $ 1,034 $ 1,029 $ 5 $ — Liabilities Foreign currency derivatives (e) $ 9 $ 9 $ — $ 9 $ — Commodity derivatives (e) 1 1 — 1 — Total liabilities at fair value $ 10 $ 10 $ — $ 10 $ — (a) Included in restricted investments and $ 61 million within other current assets in the Condensed Consolidated Balance Sheets . (b) Includes $ 245 million related to the Asbestos trust and $ 129 million related to the Environmental trust . (c) Included in other noncurrent assets in the Condensed Consolidated Balance Sheets . (d) Included in accounts receivable in the Condensed Consolidated Balance Sheets . (e) Included in accrued expenses and other liabilities in the Condensed Consolidated Balance Sheets. |
Summary of Restricted Investment Portfolio | The following table presents gross unrealized gains and losses for the restricted securities as of March 31, 2023 and September 30, 2022: Gross Gross (In millions) Adjusted Cost Unrealized Gain Unrealized Loss Fair Value As of March 31, 2023 Demand deposit $ 12 $ — $ — $ 12 Equity mutual fund 177 27 ( 4 ) 200 Fixed income mutual fund 234 — ( 36 ) 198 Fair value $ 423 $ 27 $ ( 40 ) $ 410 As of September 30, 2022 Demand deposit $ 6 $ — $ — $ 6 Equity mutual fund 186 20 ( 25 ) 181 Fixed income mutual fund 234 — ( 47 ) 187 Fair value $ 426 $ 20 $ ( 72 ) $ 374 |
Summary of Investment Income, Net Gains and Losses, Funds restricted for Specific Transactions and Disbursements Related to Investments | The following table presents the investment income, net gains and losses realized, funds restricted for specific transactions, and disbursements related to the investments within the portfolio for the three and six months ended March 31, 2023 and 2022. Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Investment income (a) $ 3 $ 2 $ 6 $ 10 Net gains (losses) (a) 19 ( 28 ) 41 ( 24 ) Funds restricted for specific transactions — 44 5 44 Disbursements ( 16 ) ( 21 ) ( 16 ) ( 28 ) (a) Included in the net interest and other expense (income) caption within the Statements of Consolidated Comprehensive Income (Loss). |
Summary of Net Gains and Losses on Foreign Currency Derivatives | The following table summarizes the net gains and losses recognized during the three and six months ended March 31, 2023 and 2022 within the Statements of Consolidated Comprehensive Income (Loss). Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Foreign currency derivative gains (losses) $ 1 $ ( 11 ) $ 9 $ ( 9 ) |
Summary of Fair Values of Outstanding Foreign Currency Derivatives | The following table summarizes the fair values of the outstanding foreign currency derivatives as of March 31, 2023 and September 30, 2022 included in accounts receivable and accrued expenses and other liabilities of the Condensed Consolidated Balance Sheets. March 31 September 30 (In millions) 2023 2022 Foreign currency derivative assets $ 2 $ 1 Notional contract values 189 133 Foreign currency derivative liabilities $ 2 $ 9 Notional contract values 140 535 |
Commodity Derivatives [Member] | |
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] | |
Summary of Net Gains and Losses on Derivatives | The following table summarizes the net gai ns and losses recognized during the three and six months ended March 31, 2023 and 2022 within the cost of sales caption of the Statements of Consolidated Comprehensive Income (Loss). Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Commodity derivative gains (losses) $ ( 1 ) $ 2 $ — $ 4 |
Summary of Fair Values of Outstanding Derivatives | The following table summarizes the fair values of the outstanding commodity derivatives as of March 31, 2023, and September 30, 2022 included in accounts receivable and accrued expenses and other liabilities of the Condensed Consolidated Balance Sheets. March 31 September 30 (In millions) 2023 2022 Commodity derivative assets $ — $ 4 Notional contract values 1 13 Commodity derivative liabilities $ 6 $ 1 Notional contract values 21 9 |
Inventories (Tables)
Inventories (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Inventory Disclosure [Abstract] | |
Summary of Inventories | The following table summarizes Ashland’s inventories as of the reported Condensed Consolidated Balance Sheet dates. March 31 September 30 (In millions) 2023 2022 Finished products $ 472 $ 391 Raw materials, supplies and work in process 258 238 $ 730 $ 629 |
Goodwill and Other Intangibles
Goodwill and Other Intangibles (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Summary of Goodwill by Reportable Segment | The following is a progression of goodwill by reportable segment for the six months ended March 31, 2023. Life Personal Specialty (In millions) Sciences Care (a) Additives (a) Intermediates (a) Total Balance at September 30, 2022 $ 787 $ 118 $ 407 $ — $ 1,312 Currency translation 45 6 22 — 73 Balance at March 31, 2023 $ 832 $ 124 $ 429 $ — $ 1,385 (a) As of March 31, 2023 and September 30, 2022, there were accumulated impairments of $ 356 million, $ 174 million and $ 90 million related to the Personal Care, Specialty Additives and Intermediates reportable segments, respectively. |
Summary of Intangible Assets | Other intangible assets were comprised of the following as of March 31, 2023 and September 30, 2022. March 31, 2023 Gross Net carrying Accumulated carrying (In millions) amount amortization amount Definite-lived intangibles Trademarks and trade names $ 98 $ ( 40 ) $ 58 Intellectual property 738 ( 561 ) 177 Customer and supplier relationships 830 ( 403 ) 427 Total definite-lived intangibles 1,666 ( 1,004 ) 662 Indefinite-lived intangibles Trademarks and trade names 278 — 278 Total intangible assets $ 1,944 $ ( 1,004 ) $ 940 September 30, 2022 Gross Net carrying Accumulated carrying (In millions) amount amortization amount Definite-lived intangibles Trademarks and trade names $ 95 $ ( 37 ) $ 58 Intellectual property 718 ( 523 ) 195 Customer and supplier relationships 801 ( 369 ) 432 Total definite-lived intangibles 1,614 ( 929 ) 685 Indefinite-lived intangibles Trademarks and trade names 278 — 278 Total intangible assets $ 1,892 $ ( 929 ) $ 963 |
Debt and Other Financing Acti_2
Debt and Other Financing Activities (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Debt Disclosure [Abstract] | |
Summary of Current and Long-term Debt | The following table summarizes Ashland’s current and long-term debt as of the dates reported in the Condensed Consolidated Balance Sheets. (In millions) March 31, 2023 September 30, 2022 3.375 % Senior Notes, due 2031 $ 450 $ 450 2.00 % Senior Notes, due 2028 (Euro 500 million principal) 545 489 6.875 % notes, due 2043 282 282 6.50 % junior subordinated notes, due 2029 62 60 Other (a) ( 11 ) ( 11 ) Total debt 1,328 1,270 Short-term debt (includes current portion of long-term debt) — — Long-term debt (less current portion) $ 1,328 $ 1,270 (a) Other includes $ 14 million of debt issuance costs as of March 31, 2023 and September 30, 2022 , respectively. |
Leasing Arrangements (Tables)
Leasing Arrangements (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Leases [Abstract] | |
Components of Lease Cost Recognized | : Three months ended Six months ended March 31 March 31 (In millions) Location 2023 2022 2023 2022 Lease cost: Operating lease cost Selling, General & Administrative $ 3 $ 3 $ 6 $ 6 Operating lease cost Cost of Sales 4 4 8 8 Variable lease cost Selling, General & Administrative 1 1 2 2 Variable lease cost Cost of Sales 1 1 2 2 Short-term leases Cost of Sales 1 1 1 1 Total lease cost $ 10 $ 10 $ 19 $ 19 |
Schedule of Cash Paid for Amounts Included in the Measurement of Operating Lease Liabilities | The following table provides cash paid for amounts included in the measurement of operating lease liabilities: Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Operating cash flows from operating leases $ 6 $ 7 $ 13 $ 14 |
Income Taxes (Tables)
Income Taxes (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Summary of Changes in Unrecognized Tax Benefits | Changes in unrecognized tax benefits are summarized as follows for the six months ended March 31, 2023. (In millions) Balance at October 1, 2022 $ 84 Increases related to positions taken in prior years 1 Decreases related to positions taken in prior years ( 27 ) Increases related to positions taken in the current year 2 Lapse of statute of limitations ( 1 ) Balance at March 31, 2023 $ 59 |
Employee Benefit Plans (Tables)
Employee Benefit Plans (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Retirement Benefits [Abstract] | |
Schedule of Components of Pension and Other Postretirement Benefit Costs for Continuing Operation | The following table details the components of pension and other postretirement benefit costs for continuing operations. Pension benefits Other postretirement (In millions) 2023 2022 2023 2022 Three months ended March 31 Service cost $ 1 $ 1 $ — $ — Interest cost 3 1 1 1 Expected return on plan assets ( 2 ) ( 2 ) — — Actuarial (gain) — ( 1 ) — — Total net periodic benefit costs $ 2 $ ( 1 ) $ 1 $ 1 Six months ended March 31 Service cost $ 2 $ 2 $ — $ — Interest cost 6 3 1 1 Expected return on plan assets ( 4 ) ( 4 ) — — Actuarial (gain) — ( 1 ) — — Total net periodic benefit costs $ 4 $ — $ 1 $ 1 For segment reporting purposes, service cost is proportionately allocated to each segment, excluding the Unallocated and other segment, and is recorded within the selling, general and administrative expense and cost of sales captions on the Statements of Consolidated Comprehensive Income (Loss). |
Litigation, Claims and Contin_2
Litigation, Claims and Contingencies (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Loss Contingencies [Line Items] | |
Reconciliation of Changes in Environmental Contingencies and Asset Retirement Obligations Reserve | The following table provides a reconciliation of the changes in the environmental remediation reserves during the six months ended March 31, 2023 and 2022. Six months ended March 31 (In millions) 2023 2022 Reserve - beginning of period $ 211 $ 207 Disbursements ( 29 ) ( 30 ) Revised obligation estimates and accretion 11 15 Reserve - end of period $ 193 $ 192 |
Components of Environmental Remediation Expense | Components of environmental remediation expense included within the selling, general and administrative expense caption of the Statements of Consolidated Comprehensive Income (Loss) are presented in the following table for the three and six ended March 31, 2023 and 2022. Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Environmental expense $ 3 $ 12 $ 11 $ 15 Legal expense 1 1 2 2 Total expense 4 13 13 17 Insurance receivable — ( 3 ) — ( 3 ) Total expense, net of receivable activity (a) $ 4 $ 10 $ 13 $ 14 |
Ashland [Member] | |
Loss Contingencies [Line Items] | |
Summary of Asbestos Claims Activity | A summary of Ashland asbestos claims activity, excluding Hercules claims, follows. Six months ended March 31 Years ended September 30 (In thousands) 2023 2022 2022 2021 2020 Open claims - beginning of year 44 46 46 49 53 New claims filed 1 1 2 2 2 Claims settled — ( 1 ) ( 1 ) ( 1 ) ( 1 ) Claims dismissed ( 2 ) ( 1 ) ( 3 ) ( 4 ) ( 5 ) Open claims - end of period 43 45 44 46 49 |
Progression of Activity in Asbestos Reserve Accounts | A progression of activity in the asbestos reserve is presented in the following table. Six months ended March 31 Years ended September 30 (In millions) 2023 2022 2022 2021 2020 Asbestos reserve - beginning of year $ 305 $ 320 $ 320 $ 335 $ 352 Reserve adjustment — — 16 12 13 Amounts paid ( 20 ) ( 19 ) ( 31 ) ( 27 ) ( 30 ) Asbestos reserve - end of period (a) $ 285 $ 301 $ 305 $ 320 $ 335 (a) Included $ 29 million classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . |
Progression of Insurance Receivable | A progression of activity in the Ashland insurance receivable is presented in the following table. Six months ended March 31 Years ended September 30 (In millions) 2023 2022 2022 2021 2020 Insurance receivable - beginning of year $ 101 $ 100 $ 100 $ 103 $ 123 Receivable adjustment (a) — — 7 6 1 Insurance settlement — — — — ( 10 ) Amounts collected ( 5 ) ( 2 ) ( 6 ) ( 9 ) ( 11 ) Insurance receivable - end of period (b) $ 96 $ 98 $ 101 $ 100 $ 103 (a) 2021 includes a $ 2 million reserve adjustment related to allowances for credit losses as a result of Ashland's adoption of the new credit measurement standard. The total allowance for credit losses was $ 2 million as of March 31, 2023 and September 30, 2022. (b) Includes $ 12 million classified in accounts receivable on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . |
Hercules [Member] | |
Loss Contingencies [Line Items] | |
Summary of Asbestos Claims Activity | A summary of Hercules’ asbestos claims activity follows. Six months ended March 31 Years ended September 30 (In thousands) 2023 2022 2022 2021 2020 Open claims - beginning of year 11 12 12 12 13 New claims filed 1 1 1 1 1 Claims dismissed — ( 1 ) ( 2 ) ( 1 ) ( 2 ) Open claims - end of period 12 12 11 12 12 |
Progression of Activity in Asbestos Reserve Accounts | A progression of activity in the asbestos reserve is presented in the following table. Six months ended March 31 Years ended September 30 (In millions) 2023 2022 2022 2021 2020 Asbestos reserve - beginning of year $ 213 $ 217 $ 217 $ 229 $ 252 Reserve adjustments — — 15 8 ( 3 ) Amounts paid ( 8 ) ( 10 ) ( 19 ) ( 20 ) ( 20 ) Asbestos reserve - end of period (a) $ 205 $ 207 $ 213 $ 217 $ 229 (a) Included $ 18 million classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . |
Progression of Insurance Receivable | A progression of activity in the Hercules insurance receivable is presented in the following table. Six months ended March 31 Years ended September 30 (In millions) 2023 2022 2022 2021 2020 Insurance receivable - beginning of year $ 52 $ 47 $ 47 $ 47 $ 49 Receivable adjustment (a) — — 7 1 ( 2 ) Amounts collected ( 1 ) ( 1 ) ( 2 ) ( 1 ) — Insurance receivable - end of period (b) $ 51 $ 46 $ 52 $ 47 $ 47 (a) 2021 includes a $ 1 million reserve adjustment related to allowances for credit losses as a result of Ashland's adoption of the new credit measurement standard. The total allowance for credit losses was $ 1 million as of March 31, 2023 and September 30, 2022 . (b) Includes $ 2 million and $ 3 million classified in accounts receivable on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 , respectively. |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Earnings Per Share [Abstract] | |
Computation of Basic and Diluted Earnings per Share | The following is the computation of basic and diluted earnings per share (EPS) from continuing operations attributable to Ashland. Stock appreciation rights (SARs), stock options and warrants available to purchase shares outstanding for each reporting period whose grant price was greater than the average market price of Ashland Common Stock for each applicable period were not included in the computation of income from continuing operations per diluted share because the effect of these instruments would be antidilutive . The total number of these shares outstanding was approximately 1 million at March 31, 2023 and 2022 , respectively. The majority of these shares are for warrants with a strike price of $ 128.66 . Earnings per share is reported under the treasury stock method. Three months ended Six months ended March 31 March 31 (In millions, except per share data) 2023 2022 2023 2022 Numerator Numerator for basic and diluted EPS - $ 92 $ 38 $ 134 $ 70 Denominator Denominator for basic EPS - Weighted- 54 56 54 57 Share based awards convertible to common shares 1 1 1 1 Denominator for diluted EPS - Adjusted weighted- 55 57 55 58 EPS from continuing operations Basic $ 1.71 $ 0.67 $ 2.47 $ 1.22 Diluted 1.68 0.66 2.43 1.20 |
Equity Items (Tables)
Equity Items (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Equity [Abstract] | |
Components of Accumulated Other Comprehensive Income (Loss) | Components of other comprehensive income (loss) recorded in the Statements of Consolidated Comprehensive Income (Loss) are presented below, before tax and net of tax effects. 2023 2022 (In millions) Before Tax Net of Before Tax Net of Three months ended March 31 Other comprehensive income (loss) Unrealized translation gain (loss) $ 27 $ — $ 27 $ ( 5 ) $ — $ ( 5 ) Unrealized gain (loss) on commodity hedges ( 4 ) 1 ( 3 ) 6 ( 1 ) 5 Total other comprehensive income (loss) $ 23 $ 1 $ 24 $ 1 $ ( 1 ) $ — Six months ended March 31 Other comprehensive income (loss) Unrealized translation gain (loss) $ 110 $ ( 1 ) $ 109 $ ( 22 ) $ 1 $ ( 21 ) Unrealized gain (loss) on commodity hedges ( 9 ) 2 ( 7 ) 1 — 1 Total other comprehensive income (loss) $ 101 $ 1 $ 102 $ ( 21 ) $ 1 $ ( 20 ) |
Summary of Reconciliation of Changes in Stockholders' Equity | A reconciliation of changes in stockholders’ equity are as follows: Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Common stock and paid in capital Balance, beginning of period $ 134 $ 328 $ 136 $ 328 Compensation expense and common shares issued (a) 4 4 2 4 Common shares purchased under repurchase program (b) (c) ( 138 ) ( 155 ) ( 138 ) ( 155 ) Balance, end of period — 177 — 177 Retained earnings Balance, beginning of period 3,675 2,827 3,653 2,796 Net income 91 786 132 834 Regular dividends ( 18 ) ( 17 ) ( 36 ) ( 34 ) Common shares purchased under repurchase program (b) ( 15 ) — ( 15 ) — Other 1 — — — Balance, end of period 3,734 3,596 3,734 3,596 Accumulated other comprehensive income (loss) Balance, beginning of period ( 491 ) ( 392 ) ( 569 ) ( 372 ) Unrealized translation gain (loss) 27 ( 5 ) 109 ( 21 ) Unrealized gain (loss) on commodity hedges ( 3 ) 5 ( 7 ) 1 Balance, end of period ( 467 ) ( 392 ) ( 467 ) ( 392 ) Total stockholders' equity $ 3,267 $ 3,381 $ 3,267 $ 3,381 Cash dividends declared per common share $ 0.335 $ 0.300 $ 0.670 $ 0.600 (a) Common shares issued were 16,937 shares and 13,935 shares for the three months ended March 31, 2023 and 2022 , respectively, and 144,514 shares and 108,650 shares for the six months ended March 31, 2023 and 2022 , respectively. (b) Common shares repurchased were 1,488,251 shares for the three and six months ended March 31, 2023, and 2,403,380 shares for the three and six months ended March 31, 2022. (c) Includes $ 1 million in excise tax on stock repurchases for the three and six months ended March 31, 2023. |
Stock Incentive Plans (Tables)
Stock Incentive Plans (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Components of Pretax Stock-Based Compensation Expense Included in Continuing Operations | The components of Ashland’s pre-tax stock-based compensation expense included in continuing operations are as follows: Three months ended Six months ended March 31 March 31 (In millions) 2023 (a) 2022 (b) 2023 (a) 2022 (b) Nonvested stock awards $ 4 $ 2 $ 7 $ 6 Performance share awards 2 3 7 5 $ 6 $ 5 $ 14 $ 11 (a) Included $ 1 million and $ 2 million of expense related to cash-settled nonvested restricted stock awards during the three and six months ended March 31, 2023 . (b) Included zero and $ 2 million of expense related to cash-settled nonvested restricted stock awards during the three and six months ended March 31, 2022 . |
Revenue (Tables)
Revenue (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue | Sales by geography Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Life Sciences North America $ 61 $ 62 $ 109 $ 115 Europe 87 66 160 121 Asia Pacific 62 52 122 98 Latin America & other 30 24 56 40 $ 240 $ 204 $ 447 $ 374 Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Personal Care North America $ 48 $ 55 $ 90 $ 96 Europe 69 69 120 125 Asia Pacific 28 30 56 62 Latin America & other 22 18 39 35 $ 167 $ 172 $ 305 $ 318 Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Specialty Additives North America $ 52 $ 61 $ 105 $ 114 Europe 61 69 109 125 Asia Pacific 39 45 74 85 Latin America & other 9 7 16 14 $ 161 $ 182 $ 304 $ 338 Three months ended Six months ended March 31 March 31 (In millions) 2023 2022 2023 2022 Intermediates North America $ 36 $ 43 $ 70 $ 74 Europe 7 10 16 19 Asia Pacific 6 11 14 21 Latin America & other 2 2 5 5 $ 51 $ 66 $ 105 $ 119 Trade receivables Trade receivables are defined as receivables arising from contracts with customers and are recorded within the accounts receivable caption within the Condensed Consolidated Balance Sheets. Ashland’s trade receivables were $ 365 million and $ 369 million as of March 31, 2023 and September 30, 2022 , respectively. See Note H for additional information on Ashland’s program to sell certain receivables on a revolving basis to third party banks up to an aggregate purchase limit (U.S Accounts Receivable Sales Program). |
Reportable Segment Information
Reportable Segment Information (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Segment Reporting [Abstract] | |
Summary of Financial Information for Each Reportable Segment | The following table presents various financial information for each reportable segment for the three and six months ended March 31, 2023 and 2022. Three months ended Six months ended March 31 March 31 (In millions - unaudited) 2023 2022 2023 2022 SALES Life Sciences $ 240 $ 204 $ 447 $ 374 Personal Care 167 172 305 318 Specialty Additives 161 182 304 338 Intermediates 51 66 105 119 Intersegment sales (a) ( 16 ) ( 20 ) ( 33 ) ( 34 ) $ 603 $ 604 $ 1,128 $ 1,115 OPERATING INCOME (LOSS) Life Sciences $ 58 $ 43 $ 92 $ 64 Personal Care 14 28 25 42 Specialty Additives 15 26 16 44 Intermediates 17 27 37 42 Unallocated and other ( 21 ) ( 24 ) ( 50 ) ( 50 ) $ 83 $ 100 $ 120 $ 142 DEPRECIATION EXPENSE Life Sciences $ 10 $ 8 $ 20 $ 16 Personal Care 10 9 20 18 Specialty Additives 14 17 28 33 Intermediates 3 3 6 7 $ 37 $ 37 $ 74 $ 74 AMORTIZATION EXPENSE Life Sciences $ 7 $ 7 $ 14 $ 14 Personal Care 11 12 22 24 Specialty Additives 5 5 9 9 Intermediates — — 1 — $ 23 $ 24 $ 46 $ 47 EBITDA (b) Life Sciences $ 75 $ 58 $ 126 $ 94 Personal Care 35 49 67 84 Specialty Additives 34 48 53 86 Intermediates 20 30 44 49 Unallocated and other ( 21 ) ( 24 ) ( 50 ) ( 50 ) $ 143 $ 161 $ 240 $ 263 March 31 September 30 (In millions - unaudited) 2023 2022 TOTAL ASSETS Life Sciences $ 1,964 $ 1,905 Personal Care 1,079 1,073 Specialty Additives 1,664 1,567 Intermediates 172 170 Unallocated and other 1,304 1,498 $ 6,183 $ 6,213 (a) Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost. (b) Excludes income (loss) from discontinued operations and other net periodic benefit loss (income). See the Statement of Consolidated Comprehensive Income (Loss) for applicable amounts excluded. |
Divestitures - Additional Infor
Divestitures - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||||
Feb. 28, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | Sep. 30, 2022 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||||
Net proceeds from sale of business | $ 1,700 | ||||||
Gain on divestitures after-tax recognized in comprehensive income (loss) | $ 732 | $ 732 | |||||
Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] | Income (loss) from discontinued operations (net of tax) | Income (loss) from discontinued operations (net of tax) | |||||
Income (loss) on acquisitions and divestitures, net | $ 0 | $ 7 | $ 0 | $ 7 | |||
Composites Segment and the Intermediates and Solvents Marl Facility [Member] | Land and Buildings [Member] | |||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||||
Net proceeds from sale of business | 11 | 11 | |||||
Income (loss) on acquisitions and divestitures, net | 7 | 7 | |||||
Performance Adhesives [Member] | |||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||||
Stranded divestitures costs | 0 | 3 | 0 | 7 | |||
Gain on divestitures after-tax recognized in comprehensive income (loss) | $ 732 | $ 732 | |||||
Specialty Additives Facility [Member] | Discontinued Operations, Held-for-sale [Member] | |||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||||
Transaction value in sale of business | $ 4 | ||||||
Specialty Additives Facility [Member] | Discontinued Operations, Held-for-sale [Member] | Selling, General and Administrative Expenses [Member] | |||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||||
Impairment charge | 0 | 4 | |||||
Specialty Additives Facility [Member] | Discontinued Operations, Held-for-sale [Member] | Maximum [Member] | |||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||||
Transaction value in sale of business | $ 1 | $ 1 | $ 1 |
Acquisitions and Divestitures -
Acquisitions and Divestitures - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Feb. 28, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Net proceeds from sale of business | $ 1,700 | ||||
Gain on divestitures recognized in comprehensive income (loss) | $ 732 | $ 732 | |||
Income (loss) on acquisitions and divestitures, net | $ 0 | 7 | $ 0 | 7 | |
Performance Adhesives [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Stranded divestitures costs | $ 0 | 3 | $ 0 | 7 | |
Gain on divestitures recognized in comprehensive income (loss) | 732 | 732 | |||
Composites Segment and the Intermediates and Solvents Marl Facility [Member] | Land and Building [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||
Net proceeds from sale of business | 11 | 11 | |||
Income (loss) on acquisitions and divestitures, net | $ 7 | $ 7 |
Discontinued Operations - Compo
Discontinued Operations - Components of Consolidated Comprehensive Income (Loss) Related to Discontinued Operations (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Income (loss) from discontinued operations (net of tax) | $ (1) | $ 748 | $ (2) | $ 764 |
Gain on disposal of discontinued operations (net of tax) | 732 | 732 | ||
Performance Adhesives [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Income (loss) from discontinued operations (net of tax) | 17 | 34 | ||
Gain on disposal of discontinued operations (net of tax) | 732 | 732 | ||
Composites/Marl facility [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Income (loss) from discontinued operations (net of tax) | $ (1) | (1) | ||
Distribution [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Income (loss) from discontinued operations (net of tax) | $ (1) | $ (1) | $ (2) |
Discontinued Operations - Recon
Discontinued Operations - Reconciliation of Consolidated Income (Loss) From Discontinued Operations (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Income (loss) from discontinued operations attributable to Performance Adhesives | ||||
Income from discontinued operations | $ (1) | $ 748 | $ (2) | $ 764 |
Performance Adhesives [Member] | ||||
Income (loss) from discontinued operations attributable to Performance Adhesives | ||||
Sales | 75 | 171 | ||
Cost of sales | (56) | (122) | ||
Selling, general and administrative expense | (6) | (11) | ||
Research and development expense | (1) | (3) | ||
Pretax income of discontinued operations | 12 | 35 | ||
Income tax (expense) benefit | 5 | (1) | ||
Income from discontinued operations | $ 17 | $ 34 |
Restructuring Activities - Addi
Restructuring Activities - Additional Information (Details) - Fiscal 2020 and 2021 Restructuring Severance Costs [Member] $ in Millions | 3 Months Ended | 6 Months Ended |
Mar. 31, 2023 USD ($) | Mar. 31, 2023 USD ($) | |
Restructuring Cost And Reserve [Line Items] | ||
Severance income (expenses) | $ 0 | $ (1) |
Restructuring reserve | $ 1 | $ 1 |
Fair Value Measurements - Summa
Fair Value Measurements - Summary of Financial Instruments Subject to Recurring Fair Value Measurements (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 | |||
Carrying (Reported) Amount, Fair Value Disclosure [Member] | |||||
Assets | |||||
Cash and cash equivalents | $ 399 | $ 646 | |||
Restricted investments | 410 | [1],[2] | 374 | [3],[4] | |
Investment of captive insurance company | 4 | [5] | 9 | [6] | |
Foreign currency derivatives | 2 | [7] | 1 | [8] | |
Total assets at fair value | 815 | 1,034 | |||
Liabilities | |||||
Foreign currency derivatives | 2 | [9] | 9 | [10] | |
Total liabilities at fair value | 8 | 10 | |||
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Commodity Derivatives [Member] | |||||
Assets | |||||
Commodity derivatives | [8] | $ 4 | |||
Derivative Asset, Statement of Financial Position [Extensible Enumeration] | Accounts Receivable, after Allowance for Credit Loss, Current | ||||
Liabilities | |||||
Commodity derivatives | [9] | $ 6 | $ 1 | ||
Derivative Liability, Statement of Financial Position [Extensible Enumeration] | Accrued Liabilities, Current | Accrued Liabilities, Current | |||
Estimate of Fair Value, Fair Value Disclosure [Member] | |||||
Assets | |||||
Cash and cash equivalents | $ 399 | $ 646 | |||
Restricted investments | 410 | [1],[2] | 374 | [3],[4] | |
Investment of captive insurance company | 4 | [5] | 9 | [6] | |
Foreign currency derivatives | 2 | [7] | 1 | [8] | |
Total assets at fair value | 815 | 1,034 | |||
Liabilities | |||||
Foreign currency derivatives | 2 | [9] | 9 | [10] | |
Total liabilities at fair value | 8 | 10 | |||
Estimate of Fair Value, Fair Value Disclosure [Member] | Commodity Derivatives [Member] | |||||
Assets | |||||
Commodity derivatives | [8] | $ 4 | |||
Derivative Asset, Statement of Financial Position [Extensible Enumeration] | Accounts Receivable, after Allowance for Credit Loss, Current | ||||
Liabilities | |||||
Commodity derivatives | [9] | $ 6 | $ 1 | ||
Derivative Liability, Statement of Financial Position [Extensible Enumeration] | Accrued Liabilities, Current | Accrued Liabilities, Current | |||
Fair Value, Inputs, Level 1 [Member] | |||||
Assets | |||||
Cash and cash equivalents | $ 399 | $ 646 | |||
Restricted investments | 410 | [1],[2] | 374 | [3],[4] | |
Investment of captive insurance company | 4 | [5] | 9 | [6] | |
Foreign currency derivatives | 0 | [7] | 0 | [8] | |
Total assets at fair value | 813 | 1,029 | |||
Liabilities | |||||
Foreign currency derivatives | 0 | [9] | 0 | [10] | |
Total liabilities at fair value | 0 | 0 | |||
Fair Value, Inputs, Level 1 [Member] | Commodity Derivatives [Member] | |||||
Assets | |||||
Commodity derivatives | [8] | 0 | |||
Liabilities | |||||
Commodity derivatives | [9] | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | |||||
Assets | |||||
Cash and cash equivalents | 0 | 0 | |||
Restricted investments | 0 | [1],[2] | 0 | [3],[4] | |
Investment of captive insurance company | 0 | [5] | 0 | [6] | |
Foreign currency derivatives | 2 | [7] | 1 | [8] | |
Total assets at fair value | 2 | 5 | |||
Liabilities | |||||
Foreign currency derivatives | 2 | [9] | 9 | [10] | |
Total liabilities at fair value | 8 | 10 | |||
Fair Value, Inputs, Level 2 [Member] | Commodity Derivatives [Member] | |||||
Assets | |||||
Commodity derivatives | [8] | 4 | |||
Liabilities | |||||
Commodity derivatives | [9] | 6 | 1 | ||
Fair Value, Inputs, Level 3 [Member] | |||||
Assets | |||||
Cash and cash equivalents | 0 | 0 | |||
Restricted investments | 0 | [1],[2] | 0 | [3],[4] | |
Investment of captive insurance company | 0 | [5] | 0 | [6] | |
Foreign currency derivatives | 0 | [7] | 0 | [8] | |
Total assets at fair value | 0 | ||||
Liabilities | |||||
Foreign currency derivatives | 0 | [9] | 0 | [10] | |
Total liabilities at fair value | 0 | 0 | |||
Fair Value, Inputs, Level 3 [Member] | Commodity Derivatives [Member] | |||||
Assets | |||||
Commodity derivatives | [8] | 0 | |||
Liabilities | |||||
Commodity derivatives | [9] | $ 0 | $ 0 | ||
[1] Included in restricted investments and $ 61 million within other current assets in the Condensed Consolidated Balance Sheets Includes $ 267 million related to the Asbestos trust and $ 143 million related to the Environmental trust Included in restricted investments and $ 61 million within other current assets in the Condensed Consolidated Balance Sheets Includes $ 245 million related to the Asbestos trust and $ 129 million related to the Environmental trust Included in other noncurrent assets in the Condensed Consolidated Balance Sheets Included in other noncurrent assets in the Condensed Consolidated Balance Sheets Included in accounts receivable in the Condensed Consolidated Balance Sheets Included in accounts receivable in the Condensed Consolidated Balance Sheets Included in accrued expenses and other liabilities in the Condensed Consolidated Balance Sheets. Included in accrued expenses and other liabilities in the Condensed Consolidated Balance Sheets. |
Fair Value Measurements - Sum_2
Fair Value Measurements - Summary of Financial Instruments Subject to Recurring Fair Value Measurements (Parenthetical) (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Restricted Investments, Current | $ 61 | $ 61 |
Asbestos Trust [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale securities, fair value | 267 | 245 |
Environmental Trust [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Available-for-sale securities, fair value | $ 143 | $ 129 |
Fair Value Measurements - Sum_3
Fair Value Measurements - Summary of Restricted Investment Portfolio (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Restricted Securities [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted cost | $ 423 | $ 426 |
Gross Unrealized Gain | 27 | 20 |
Gross Unrealized Loss | (40) | (72) |
Fair Value | 410 | 374 |
Fixed Income Mutual Fund [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted cost | 234 | 234 |
Gross Unrealized Gain | 0 | 0 |
Gross Unrealized Loss | (36) | (47) |
Fair Value | 198 | 187 |
Equity Mutual Fund [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted cost | 177 | 186 |
Gross Unrealized Gain | 27 | 20 |
Gross Unrealized Loss | (4) | (25) |
Fair Value | 200 | 181 |
Demand Deposit [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted cost | 12 | 6 |
Gross Unrealized Gain | 0 | 0 |
Gross Unrealized Loss | 0 | 0 |
Fair Value | $ 12 | $ 6 |
Fair Value Measurements - Sum_4
Fair Value Measurements - Summary of Investment Income, Net Gains and Losses, Funds restricted for Specific Transactions and Disbursements Related to Investments (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | ||
Fair Value Disclosures [Abstract] | |||||
Investment income | [1] | $ 3 | $ 2 | $ 6 | $ 10 |
Net gains (losses) | [1] | 19 | (28) | 41 | (24) |
Funds restricted for specific transactions | 0 | 44 | 5 | 44 | |
Disbursements | $ (16) | $ (21) | $ (16) | $ (28) | |
[1] Included in the net interest and other expense (income) caption within the Statements of Consolidated Comprehensive Income (Loss). |
Fair Value Measurements - Sum_5
Fair Value Measurements - Summary of Investment Portfolio (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | ||
Fair Value Disclosures [Abstract] | |||||
Investment income | [1] | $ 3 | $ 2 | $ 6 | $ 10 |
Funds restricted for specific transactions | 0 | 44 | 5 | 44 | |
Disbursements | $ (16) | $ (21) | $ (16) | $ (28) | |
[1] Included in the net interest and other expense (income) caption within the Statements of Consolidated Comprehensive Income (Loss). |
Fair Value Measurements - Sum_6
Fair Value Measurements - Summary of Investment Portfolio (Parenthetical) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Funds restricted for specific transactions | $ 0 | $ 44 | $ 5 | $ 44 |
Fair Value Measurements - Sum_7
Fair Value Measurements - Summary of Net Gains and Losses on Foreign Currency Derivatives (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member] | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Foreign currency derivative gains (losses) | $ 1 | $ (11) | $ 9 | $ (9) |
Fair Value Measurements - Sum_8
Fair Value Measurements - Summary of Fair Values of Outstanding Foreign Currency Derivatives (Details) - Foreign Exchange Contract [Member] - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Accounts Receivable [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Foreign currency derivative assets | $ 2 | $ 1 |
Notional contract values | 189 | 133 |
Accrued Expenses and Other Liabilities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Notional contract values | 140 | 535 |
Foreign currency derivative liabilities | $ 2 | $ 9 |
Fair Value Measurements - Sum_9
Fair Value Measurements - Summary of Net Gains and Losses on Derivatives (Details) - Commodity Derivatives [Member] - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Commodity derivative gains (losses) | $ (1) | $ 2 | $ 0 | $ 4 |
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] | Cost of Revenue | Cost of Revenue | Cost of Revenue | Cost of Revenue |
Fair Value Measurements - Su_10
Fair Value Measurements - Summary of Fair Values of Outstanding Commodity Derivatives (Details) - Commodity Contract [Member] - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Accounts Receivable [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Commodity derivative assets | $ 0 | $ 4 |
Notional contract values | 1 | 13 |
Accrued Expenses and Other Liabilities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Notional contract values | 21 | 9 |
Commodity derivative liabilities | $ 6 | $ 1 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Investments, Debt and Equity Securities [Abstract] | ||
Restricted Investments, Current | $ 61 | $ 61 |
Long-term debt, carrying value | 1,342 | 1,284 |
Long-term debt, fair value | $ 1,224 | $ 1,102 |
Inventories - Summary of Invent
Inventories - Summary of Inventories (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Inventory Disclosure [Abstract] | ||
Finished products | $ 472 | $ 391 |
Raw materials, supplies and work in process | 258 | 238 |
Total | $ 730 | $ 629 |
Goodwill and Other Intangible_2
Goodwill and Other Intangibles - Summary of Goodwill by Reportable Segment (Details) $ in Millions | 6 Months Ended | |
Mar. 31, 2023 USD ($) | ||
Goodwill [Roll Forward] | ||
Balance at beginning of period | $ 1,312 | |
Currency translation | 73 | |
Balance at end of period | 1,385 | |
Life Sciences [Member] | ||
Goodwill [Roll Forward] | ||
Balance at beginning of period | 787 | |
Currency translation | 45 | |
Balance at end of period | 832 | |
Personal Care [Member] | ||
Goodwill [Roll Forward] | ||
Balance at beginning of period | 118 | [1] |
Currency translation | 6 | [1] |
Balance at end of period | 124 | [1] |
Specialty Additives [Member] | ||
Goodwill [Roll Forward] | ||
Balance at beginning of period | 407 | [1] |
Currency translation | 22 | [1] |
Balance at end of period | 429 | [1] |
Intermediates [Member] | ||
Goodwill [Roll Forward] | ||
Balance at beginning of period | 0 | [1] |
Currency translation | 0 | [1] |
Balance at end of period | $ 0 | [1] |
[1] As of March 31, 2023 and September 30, 2022, there were accumulated impairments of $ 356 million, $ 174 million and $ 90 million related to the Personal Care, Specialty Additives and Intermediates reportable segments, respectively. |
Goodwill and Other Intangible_3
Goodwill and Other Intangibles - Summary of Goodwill by Reportable Segment (Parenthetical) (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Personal Care [Member] | ||
Goodwill [Line Items] | ||
Accumulated impairment | $ 356 | $ 356 |
Specialty Additives [Member] | ||
Goodwill [Line Items] | ||
Accumulated impairment | 174 | 174 |
Intermediates [Member] | ||
Goodwill [Line Items] | ||
Accumulated impairment | $ 90 | $ 90 |
Goodwill and Other Intangible_4
Goodwill and Other Intangibles - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Finite-Lived Intangible Assets, Net [Abstract] | ||||
Intangibles amortization expense - Note G | $ 23 | $ 24 | $ 46 | $ 47 |
Expected future amortization expense [Abstract] | ||||
2023 (includes six months actual and six months estimated) | 93 | 93 | ||
2024 | 79 | 79 | ||
2025 | 74 | 74 | ||
2026 | 71 | 71 | ||
2027 | $ 50 | $ 50 | ||
Minimum [Member] | Trademarks and Trade Names [Member] | ||||
Intangible Assets, Net [Abstract] | ||||
Useful life (in years) | 3 years | |||
Minimum [Member] | Intellectual Property [Member] | ||||
Intangible Assets, Net [Abstract] | ||||
Useful life (in years) | 3 years | |||
Minimum [Member] | Customer and Supplier Relationships [Member] | ||||
Intangible Assets, Net [Abstract] | ||||
Useful life (in years) | 10 years | |||
Maximum [Member] | Trademarks and Trade Names [Member] | ||||
Intangible Assets, Net [Abstract] | ||||
Useful life (in years) | 20 years | |||
Maximum [Member] | Intellectual Property [Member] | ||||
Intangible Assets, Net [Abstract] | ||||
Useful life (in years) | 20 years | |||
Maximum [Member] | Customer and Supplier Relationships [Member] | ||||
Intangible Assets, Net [Abstract] | ||||
Useful life (in years) | 24 years |
Goodwill and Other Intangible_5
Goodwill and Other Intangibles - Summary of Intangible Assets (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Finite Lived Intangible Assets [Line Items] | ||
Gross carrying amount | $ 1,666 | $ 1,614 |
Accumulated amortization | (1,004) | (929) |
Net carrying amount | 662 | 685 |
Intangible Assets, Net [Abstract] | ||
Gross carrying amount | 1,944 | 1,892 |
Net carrying amount | 940 | 963 |
Trademarks and Trade Names [Member] | ||
Finite Lived Intangible Assets [Line Items] | ||
Gross carrying amount | 98 | 95 |
Accumulated amortization | (40) | (37) |
Net carrying amount | 58 | 58 |
Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] | ||
Indefinite-lived intangible assets | 278 | 278 |
Intellectual Property [Member] | ||
Finite Lived Intangible Assets [Line Items] | ||
Gross carrying amount | 738 | 718 |
Accumulated amortization | (561) | (523) |
Net carrying amount | 177 | 195 |
Customer and Supplier Relationships [Member] | ||
Finite Lived Intangible Assets [Line Items] | ||
Gross carrying amount | 830 | 801 |
Accumulated amortization | (403) | (369) |
Net carrying amount | $ 427 | $ 432 |
Debt and Other Financing Acti_3
Debt and Other Financing Activities - Summary of Current and Long-term Debt (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 | |
Debt Instrument [Line Items] | |||
Carrying value of debt | $ 1,342 | $ 1,284 | |
Other | [1] | (11) | (11) |
Total debt | 1,328 | 1,270 | |
Short-term debt (includes current portion of long-term debt) | 0 | 0 | |
Long-term debt (less current portion) | 1,328 | 1,270 | |
3.375% Senior Notes, due 2031 [Member] | |||
Debt Instrument [Line Items] | |||
Carrying value of debt | 450 | 450 | |
2.00% Senior Notes Due 2028 [Member] | |||
Debt Instrument [Line Items] | |||
Carrying value of debt | 545 | 489 | |
6.875% Notes due 2043 [Member] | |||
Debt Instrument [Line Items] | |||
Carrying value of debt | 282 | 282 | |
6.50% Junior Subordinated Notes, Due 2029 [Member] | |||
Debt Instrument [Line Items] | |||
Carrying value of debt | $ 62 | $ 60 | |
[1] Other includes $ 14 million of debt issuance costs as of March 31, 2023 and September 30, 2022 , respectively. |
Debt and Other Financing Acti_4
Debt and Other Financing Activities - Summary of Current and Long-term Debt (Parenthetical) (Details) € in Millions, $ in Millions | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2023 EUR (€) | Sep. 30, 2022 EUR (€) | Mar. 31, 2023 USD ($) | Sep. 30, 2022 USD ($) | |
Debt Instrument [Line Items] | ||||
Unamortized debt issuance expense, long-term debt | $ | $ 14 | $ 14 | ||
3.375% Senior Notes, due 2031 [Member] | ||||
Debt Instrument [Line Items] | ||||
Debt instrument, interest rate, stated percentage | 3.375% | 3.375% | 3.375% | 3.375% |
Debt instrument, maturity year | 2031 | 2031 | ||
2.00% Senior Notes Due 2028 [Member] | ||||
Debt Instrument [Line Items] | ||||
Debt instrument, interest rate, stated percentage | 2% | 2% | 2% | 2% |
Debt instrument, maturity year | 2028 | 2028 | ||
Principal amount | € | € 500 | € 500 | ||
6.875% Notes due 2043 [Member] | ||||
Debt Instrument [Line Items] | ||||
Debt instrument, interest rate, stated percentage | 6.875% | 6.875% | 6.875% | 6.875% |
Debt instrument, maturity year | 2043 | 2043 | ||
6.50% Junior Subordinated Notes, Due 2029 [Member] | ||||
Debt Instrument [Line Items] | ||||
Debt instrument, interest rate, stated percentage | 6.50% | 6.50% | 6.50% | 6.50% |
Debt instrument, maturity year | 2029 | 2029 |
Debt and Other Financing Acti_5
Debt and Other Financing Activities - Summary of Current and Long-term Debt - Additional Information (Details) $ in Millions | Mar. 31, 2023 USD ($) |
Scheduled aggregate debt maturities by fiscal year [Abstract] | |
Remaining in 2023 | $ 0 |
2024 | 0 |
2025 | 0 |
2026 | 0 |
2027 | $ 4 |
Debt and Other Financing Acti_6
Debt and Other Financing Activities - U.S. Accounts Receivable Sales Program - Additional Information (Details) - U.S. Accounts Receivable Sales Program [Member] - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Apr. 14, 2023 | Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Sep. 30, 2022 | |
Disclosure Of Sales Program Of Receivable [Line Items] | ||||||
Maximum limit of receivables can transfer | $ 125,000,000 | $ 125,000,000 | ||||
Gain (loss) on sale of receivables | 1,000,000 | |||||
Sales against the buyers limit | 88,000,000 | 110,000,000 | ||||
Amount transferred in receivables | 113,000,000 | 136,000,000 | ||||
Gross cash proceeds received for receivables transferred and derecognized | 99,000,000 | |||||
Cash proceeds collected | 122,000,000 | |||||
Payments for (proceeds from) new transfers of receivables | 22,000,000 | |||||
Subsequent Event [Member] | ||||||
Disclosure Of Sales Program Of Receivable [Line Items] | ||||||
Reduction of sales of buyer's limit | $ 100,000,000 | |||||
Maximum [Member] | ||||||
Disclosure Of Sales Program Of Receivable [Line Items] | ||||||
Gain (loss) on sale of receivables | $ 1,000,000 | $ 1,000,000 | $ 1,000,000 | |||
Recorded liabilities related to service obligations and limited guarantee | $ 1,000,000 | $ 1,000,000 | $ 1,000,000 | |||
Maximum [Member] | Subsequent Event [Member] | ||||||
Disclosure Of Sales Program Of Receivable [Line Items] | ||||||
Reduction of sales of buyer's limit | $ 115,000,000 |
Debt and Other Financing Acti_7
Debt and Other Financing Activities - Foreign Accounts Receivable Securitization Facility - Additional Information (Details) - USD ($) $ in Millions | 6 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2023 | Sep. 30, 2022 | |
Debt Instrument [Line Items] | |||
Repayment of outstanding principal balance | $ 250 | ||
2018 Accounts Receivable Securitization [Member] | |||
Debt Instrument [Line Items] | |||
Outstanding amount of receivables sold to affiliate | $ 150 | $ 162 |
Debt and Other Financing Acti_8
Debt and Other Financing Activities - Financing Activity and Covenants - Additional Information (Details) | Mar. 31, 2023 USD ($) |
Debt Instrument [Line Items] | |
Line of credit facility, remaining borrowing capacity | $ 690,000,000 |
Liquidity under accounts receivable sales program | $ 0 |
Covenant restrictions [Abstract] | |
Maximum consolidated leverage ratio | 4 |
Consolidated net leverage ratio | 1.6 |
Minimum required consolidated interest coverage ratio | 3 |
Consolidated interest coverage ratio | 10.6 |
Revolving Credit Facility [Member] | |
Debt Instrument [Line Items] | |
Line of credit facility, maximum borrowing capacity | $ 600,000,000 |
Line of credit facility, remaining borrowing capacity | 582,000,000 |
Debt instrument, outstanding principal amount | 0 |
Letters of credit outstanding, amount | 18,000,000 |
2018 Accounts Receivable Securitization [Member] | |
Debt Instrument [Line Items] | |
Line of credit facility, remaining borrowing capacity | $ 108,000,000 |
Leasing Arrangements - Addition
Leasing Arrangements - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Lessee Lease Description [Line Items] | ||||
Right-of-use assets exchanged for new operating lease obligations | $ 20 | $ 3 | $ 23 | $ 4 |
Leasing Arrangements - Componen
Leasing Arrangements - Components of Lease Cost Recognized (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Lease cost: | ||||
Total lease cost | $ 10 | $ 10 | $ 19 | $ 19 |
Selling General and Administrative Expenses {Member] | ||||
Lease cost: | ||||
Operating lease cost | 3 | 3 | 6 | 6 |
Variable lease cost | 1 | 1 | 2 | 2 |
Cost of Sales [Member] | ||||
Lease cost: | ||||
Operating lease cost | 4 | 4 | 8 | 8 |
Variable lease cost | 1 | 1 | 2 | 2 |
Short-term leases | $ 1 | $ 1 | $ 1 | $ 1 |
Leasing Arrangements - Schedule
Leasing Arrangements - Schedule of Cash Paid for Amounts Included in the Measurement of Operating Lease Liabilities (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Leases [Abstract] | ||||
Operating cash flows from operating leases | $ 6 | $ 7 | $ 13 | $ 14 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Minimum [Member] | ||||
Income Tax Contingency [Line Items] | ||||
Decrease in unrecognized tax benefits is reasonably possible | $ 3 | $ 3 | ||
Maximum [Member] | ||||
Income Tax Contingency [Line Items] | ||||
Decrease in unrecognized tax benefits is reasonably possible | $ 5 | $ 5 | ||
Current Fiscal Year [Member] | ||||
Income Tax Contingency [Line Items] | ||||
Effective tax rate (in hundredths) | (1.00%) | (5.00%) | ||
Tax reform (benefit) and expense | $ 20 | $ 23 | ||
Prior Fiscal Year [Member] | ||||
Income Tax Contingency [Line Items] | ||||
Effective tax rate (in hundredths) | 34% | 25% | ||
Tax reform (benefit) and expense | $ 7 | $ 5 |
Income Taxes - Summary of Chang
Income Taxes - Summary of Changes in Unrecognized Tax Benefits (Details) $ in Millions | 6 Months Ended |
Mar. 31, 2023 USD ($) | |
Income Tax Disclosure [Abstract] | |
Balance at beginning of period | $ 84 |
Increases related to positions taken in prior years | 1 |
Decreases related to positions taken in prior years | (27) |
Increases related to positions taken in the current year | 2 |
Lapse of statute of limitations | (1) |
Balance at end of period | $ 59 |
Employee Benefit Plans - Additi
Employee Benefit Plans - Additional Information (Details) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 USD ($) | Mar. 31, 2022 USD ($) | Mar. 31, 2023 USD ($) Employee | Mar. 31, 2022 USD ($) | |
Defined Benefit Plan Disclosure [Line Items] | ||||
Actual contributions to benefit plans in period | $ 0 | |||
Estimated future contributions in current fiscal year | $ 3 | $ 3 | ||
Number of employees transferred upon divestiture | Employee | 40 | |||
Actuarial gain | $ 1 | $ 1 | ||
Other net periodic benefit (loss) income | (2) | $ 1 | $ (3) | $ 1 |
Foreign Pension Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Actual contributions to benefit plans in period | 3 | |||
Estimated future contributions in current fiscal year | $ 1 | $ 1 |
Employee Benefit Plans - Schedu
Employee Benefit Plans - Schedule of Components of Pension and Other Postretirement Benefit Costs for Continuing Operation (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Defined Benefit Plan Disclosure [Line Items] | ||||
Actuarial (gain) | $ (1) | $ (1) | ||
Pension Plan | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Service cost | $ 1 | 1 | $ 2 | 2 |
Interest cost | 3 | 1 | 6 | 3 |
Expected return on plan assets | (2) | (2) | (4) | (4) |
Actuarial (gain) | 0 | (1) | 0 | (1) |
Total net periodic benefit costs | 2 | (1) | 4 | 0 |
Other Postretirement Benefits Plan [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Service cost | 0 | 0 | 0 | 0 |
Interest cost | 1 | 1 | 1 | 1 |
Expected return on plan assets | 0 | 0 | 0 | 0 |
Actuarial (gain) | 0 | 0 | 0 | 0 |
Total net periodic benefit costs | $ 1 | $ 1 | $ 1 | $ 1 |
Litigation, Claims and Contin_3
Litigation, Claims and Contingencies - Summary of Asbestos Claims Activity (Details) - Claim Claim in Thousands | 6 Months Ended | 12 Months Ended | |||
Mar. 31, 2023 | Mar. 31, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 | |
Ashland [Member] | |||||
Asbestos claims [Roll Forward] | |||||
Open claims - beginning of year | 44 | 46 | 46 | 49 | 53 |
New claims filed | 1 | 1 | 2 | 2 | 2 |
Claims settled | 0 | (1) | (1) | (1) | (1) |
Claims dismissed | (2) | (1) | (3) | (4) | (5) |
Open claims - end of period | 43 | 45 | 44 | 46 | 49 |
Hercules [Member] | |||||
Asbestos claims [Roll Forward] | |||||
Open claims - beginning of year | 11 | 12 | 12 | 12 | 13 |
New claims filed | 1 | 1 | 1 | 1 | 1 |
Claims dismissed | 0 | (1) | (2) | (1) | (2) |
Open claims - end of period | 12 | 12 | 11 | 12 | 12 |
Litigation, Claims and Contin_4
Litigation, Claims and Contingencies - Additional Information (Details) $ in Millions | 6 Months Ended | 12 Months Ended | |||||||||
Mar. 31, 2023 USD ($) Facility Site ServiceStationProperty | Mar. 31, 2022 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | ||||||
Asbestos litigation cost projection [Abstract] | |||||||||||
Number of Years Included in Asbestos Assumption | 40 years | ||||||||||
Environmental Remediation Costs Recognized [Abstract] | |||||||||||
Number of sites were company is identified as a potentially responsible party under the superfund or similar state law | Site | 58 | ||||||||||
Number of current and former operating facilities subject to various environmental laws | Facility | 108 | ||||||||||
Total number of service station properties subject to various environmental laws | ServiceStationProperty | 1,225 | ||||||||||
Number of service stations being actively remediated | ServiceStationProperty | 17 | ||||||||||
Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration] | Other liabilities | ||||||||||
Accrual for environmental loss contingencies | $ 193 | $ 192 | $ 211 | $ 207 | |||||||
Accrued environmental loss contingencies, noncurrent | 144 | 157 | |||||||||
Recorded third-party environmental recoveries receivable | 19 | 21 | |||||||||
Recorded third-party environmental recoveries, noncurrent | 16 | 17 | |||||||||
Environmental exit costs, reasonably possible additional loss | $ 445 | ||||||||||
Maximum reserve for remediation reserve related to any one site (in hundredths) | 14% | ||||||||||
Ashland [Member] | |||||||||||
Asbestos reserve [Roll Forward] | |||||||||||
Increase (decrease) in asbestos related reserve | $ 0 | 0 | 16 | 12 | $ 13 | ||||||
Movement in Loss Contingency Receivable, Increase (Decrease) [Roll Forward] | |||||||||||
Insurance receivable | 96 | [1] | 98 | [1] | 101 | [1] | 100 | [1] | 103 | [1] | $ 123 |
Receivable adjustment | 7 | ||||||||||
Asbestos litigation cost projection [Abstract] | |||||||||||
Possible total future litigation defense and claim settlement costs | 456 | ||||||||||
Total reserves for asbestos claims | 285 | [2] | 301 | [2] | 305 | [2] | 320 | [2] | 335 | [2] | 352 |
Hercules [Member] | |||||||||||
Asbestos reserve [Roll Forward] | |||||||||||
Increase (decrease) in asbestos related reserve | 0 | 0 | 15 | 8 | (3) | ||||||
Movement in Loss Contingency Receivable, Increase (Decrease) [Roll Forward] | |||||||||||
Insurance receivable | 51 | [3] | 46 | [3] | 52 | [3] | 47 | [3] | 47 | [3] | 49 |
Receivable adjustment | 7 | ||||||||||
Asbestos litigation cost projection [Abstract] | |||||||||||
Possible total future litigation defense and claim settlement costs | 317 | ||||||||||
Total reserves for asbestos claims | $ 205 | [4] | $ 207 | [4] | $ 213 | [4] | $ 217 | [4] | $ 229 | [4] | $ 252 |
[1] Includes $ 12 million classified in accounts receivable on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . Included $ 29 million classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . Includes $ 2 million and $ 3 million classified in accounts receivable on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 , respectively. Included $ 18 million classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . |
Litigation, Claims and Contin_5
Litigation, Claims and Contingencies - Schedule of Progression of Activity in the Asbestos Reserve (Details) - USD ($) $ in Millions | 6 Months Ended | 12 Months Ended | ||||||||
Mar. 31, 2023 | Mar. 31, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 | ||||||
Ashland [Member] | ||||||||||
Asbestos reserve [Roll Forward] | ||||||||||
Asbestos reserve - beginning of year | $ 305 | [1] | $ 320 | [1] | $ 320 | [1] | $ 335 | [1] | $ 352 | |
Reserve adjustment | 0 | 0 | 16 | 12 | 13 | |||||
Amounts paid | (20) | (19) | (31) | (27) | (30) | |||||
Asbestos reserve - end of period | [1] | 285 | 301 | 305 | 320 | 335 | ||||
Hercules [Member] | ||||||||||
Asbestos reserve [Roll Forward] | ||||||||||
Asbestos reserve - beginning of year | 213 | [2] | 217 | [2] | 217 | [2] | 229 | [2] | 252 | |
Reserve adjustment | 0 | 0 | 15 | 8 | (3) | |||||
Amounts paid | (8) | (10) | (19) | (20) | (20) | |||||
Asbestos reserve - end of period | [2] | $ 205 | $ 207 | $ 213 | $ 217 | $ 229 | ||||
[1] Included $ 29 million classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . Included $ 18 million classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . |
Litigation, Claims and Contin_6
Litigation, Claims and Contingencies - Schedule of Progression of Activity in the Asbestos Reserve (Parenthetical) (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2019 | |||||
Ashland [Member] | |||||||||||
Asbestos reserve [Roll Forward] | |||||||||||
Asbestos reserve | $ 285 | [1] | $ 305 | [1] | $ 301 | [1] | $ 320 | [1] | $ 335 | [1] | $ 352 |
Ashland [Member] | Other Current Liabilities [Member] | |||||||||||
Asbestos reserve [Roll Forward] | |||||||||||
Asbestos reserve | 29 | 29 | |||||||||
Hercules [Member] | |||||||||||
Asbestos reserve [Roll Forward] | |||||||||||
Asbestos reserve | 205 | [2] | 213 | [2] | $ 207 | [2] | $ 217 | [2] | $ 229 | [2] | $ 252 |
Hercules [Member] | Other Current Liabilities [Member] | |||||||||||
Asbestos reserve [Roll Forward] | |||||||||||
Asbestos reserve | $ 18 | $ 18 | |||||||||
[1] Included $ 29 million classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . Included $ 18 million classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . |
Litigation, Claims and Contin_7
Litigation, Claims and Contingencies - Summary of Progression of Insurance Receivable (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 | ||||||
Movement in Loss Contingency Receivable, Increase (Decrease) [Roll Forward] | ||||||||||||
Insurance settlement | $ 0 | $ 3 | $ 0 | $ 3 | ||||||||
Ashland [Member] | ||||||||||||
Movement in Loss Contingency Receivable, Increase (Decrease) [Roll Forward] | ||||||||||||
Insurance receivable - beginning of year | 101 | [1] | 100 | [1] | $ 100 | [1] | $ 103 | [1] | $ 123 | |||
Receivable adjustment | [2] | 0 | 0 | 7 | 6 | 1 | ||||||
Insurance settlement | 0 | 0 | 0 | 0 | (10) | |||||||
Amounts collected | (5) | (2) | (6) | (9) | (11) | |||||||
Insurance receivable - end of period | [1] | 96 | 98 | 96 | 98 | 101 | 100 | 103 | ||||
Hercules [Member] | ||||||||||||
Movement in Loss Contingency Receivable, Increase (Decrease) [Roll Forward] | ||||||||||||
Insurance receivable - beginning of year | 52 | [3] | 47 | [3] | 47 | [3] | 47 | [3] | 49 | |||
Receivable adjustment | [4] | 0 | 0 | 7 | 1 | (2) | ||||||
Amounts collected | (1) | (1) | (2) | (1) | 0 | |||||||
Insurance receivable - end of period | [3] | $ 51 | $ 46 | $ 51 | $ 46 | $ 52 | $ 47 | $ 47 | ||||
[1] Includes $ 12 million classified in accounts receivable on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . 2021 includes a $ 2 million reserve adjustment related to allowances for credit losses as a result of Ashland's adoption of the new credit measurement standard. The total allowance for credit losses was $ 2 million as of March 31, 2023 and September 30, 2022. Includes $ 2 million and $ 3 million classified in accounts receivable on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 , respectively. 2021 includes a $ 1 million reserve adjustment related to allowances for credit losses as a result of Ashland's adoption of the new credit measurement standard. The total allowance for credit losses was $ 1 million as of March 31, 2023 and September 30, 2022 . |
Litigation, Claims and Contin_8
Litigation, Claims and Contingencies - Summary of Progression of Insurance Receivable (Parenthetical) (Details) - USD ($) $ in Millions | 12 Months Ended | |||||||||||
Sep. 30, 2021 | Mar. 31, 2023 | Sep. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2020 | Sep. 30, 2019 | |||||||
Ashland [Member] | ||||||||||||
Movement in Loss Contingency Receivable, Increase (Decrease) [Roll Forward] | ||||||||||||
Insurance receivable | $ 100 | [1] | $ 96 | [1] | $ 101 | [1] | $ 98 | [1] | $ 103 | [1] | $ 123 | |
Allowance for credit losses | 2 | |||||||||||
Total allowance for credit losses | 2 | 2 | ||||||||||
Ashland [Member] | Accounts Receivable [Member] | ||||||||||||
Movement in Loss Contingency Receivable, Increase (Decrease) [Roll Forward] | ||||||||||||
Insurance receivable | [1] | 12 | 12 | |||||||||
Hercules [Member] | ||||||||||||
Movement in Loss Contingency Receivable, Increase (Decrease) [Roll Forward] | ||||||||||||
Insurance receivable | 47 | [2] | 51 | [2] | 52 | [2] | $ 46 | [2] | $ 47 | [2] | $ 49 | |
Allowance for credit losses | $ 1 | |||||||||||
Total allowance for credit losses | 1 | 1 | ||||||||||
Hercules [Member] | Accounts Receivable [Member] | ||||||||||||
Movement in Loss Contingency Receivable, Increase (Decrease) [Roll Forward] | ||||||||||||
Insurance receivable | $ 2 | $ 3 | ||||||||||
[1] Includes $ 12 million classified in accounts receivable on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 . Includes $ 2 million and $ 3 million classified in accounts receivable on the Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 , respectively. |
Litigation, Claims and Contin_9
Litigation, Claims and Contingencies - Summary of Reconciliation of Changes in Environmental Remediation Reserves (Details) - USD ($) $ in Millions | 6 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Loss Contingencies [Line Items] | ||
Reserve - beginning of period | $ 211 | $ 207 |
Disbursements | (29) | (30) |
Revised obligation estimates and accretion | 11 | 15 |
Reserve - end of period | $ 193 | $ 192 |
Litigation, Claims and Conti_10
Litigation, Claims and Contingencies - Summary of Components of Environmental Remediation Expense Included within Selling, General and Administrative Expense (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | ||
Loss Contingencies [Line Items] | |||||
Environmental expense | $ 3 | $ 12 | $ 11 | $ 15 | |
Legal expense | 1 | 1 | 2 | 2 | |
Total expense | 4 | 13 | 13 | 17 | |
Insurance receivable | 0 | (3) | 0 | (3) | |
Total expense, net of receivable activity | [1] | $ 4 | $ 10 | $ 13 | $ 14 |
[1] Net expense of zero and $ 1 million for the three and six months ended March 31, 2023 , respectively, and $ 1 million and $ 2 million for the three and six months ended March 31, 2022, respectively, relates to divested businesses which qualified for treatment as discontinued operations for which certain environmental liabilities were retained by Ashland. These amounts are classified within the income (loss) from discontinued operations caption of the Statements of Consolidated Comprehensive Income (loss). |
Litigation, Claims and Conti_11
Litigation, Claims and Contingencies - Summary of Components of Environmental Remediation Expense Included within Selling, General and Administrative Expense (Parenthetical) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Loss Contingencies [Line Items] | ||||
Net expense relates to divested businesses | $ 0 | $ 1 | $ 1 | $ 2 |
Earnings Per Share - Additional
Earnings Per Share - Additional Information (Details) - $ / shares shares in Millions | 6 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Earnings Per Share [Abstract] | ||
Shares, Outstanding | 1 | 1 |
Shares of warrants with a strike price | $ 128.66 |
Earnings Per Share - Computatio
Earnings Per Share - Computation of Basic and Diluted Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Numerator | ||||
Numerator for basic and diluted EPS - Income from continuing operations | $ 92 | $ 38 | $ 134 | $ 70 |
Denominator | ||||
Denominator for basic EPS - Weighted-average common shares outstanding | 54 | 56 | 54 | 57 |
Share based awards convertible to common shares | 1 | 1 | 1 | 1 |
Denominator for diluted EPS - Adjusted weighted-average shares and assumed conversions | 55 | 57 | 55 | 58 |
Earnings Per Share from Continuing Operations [Abstract] | ||||
Basic | $ 1.71 | $ 0.67 | $ 2.47 | $ 1.22 |
Diluted | $ 1.68 | $ 0.66 | $ 2.43 | $ 1.20 |
Equity Items - Additional Infor
Equity Items - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended | |||||||||
Mar. 31, 2022 | Apr. 30, 2023 | Mar. 31, 2023 | Feb. 28, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Mar. 31, 2023 | Mar. 31, 2022 | Sep. 30, 2022 | Mar. 01, 2022 | |
Accelerated Share Repurchases [Line Items] | ||||||||||||
Accrued expenses and other liabilities | $ 206 | $ 206 | $ 206 | $ 269 | ||||||||
Common shares repurchased | 1,488,251 | 2,403,380 | 1,488,251 | 2,403,380 | ||||||||
Dividend per common share | $ 0.335 | $ 0.335 | $ 0.300 | $ 0.300 | ||||||||
2022 Stock Repurchase Program [Member] | ||||||||||||
Accelerated Share Repurchases [Line Items] | ||||||||||||
Stock repurchase during period value | 52 | $ 100 | ||||||||||
Aggregate amount of common stock to be repurchased | 100 | $ 100 | $ 100 | $ 100 | ||||||||
Cash settled | 42 | |||||||||||
Accrued expenses and other liabilities | $ 10 | $ 10 | $ 10 | |||||||||
Stock repurchased and retired during period shares | 500,000 | 1,000,000 | ||||||||||
2022 Stock Repurchase Program [Member] | Subsequent Event [Member] | ||||||||||||
Accelerated Share Repurchases [Line Items] | ||||||||||||
Stock repurchase during period value | $ 100 | |||||||||||
Stock repurchased and retired during period shares | 1,000,000 | |||||||||||
2018 Stock Repurchase Program [Member] | ||||||||||||
Accelerated Share Repurchases [Line Items] | ||||||||||||
Stock repurchase during period value | $ 155 | |||||||||||
Aggregate amount of common stock to be repurchased | $ 200 | |||||||||||
Stock repurchased and retired during period shares | 1,700,000 |
Equity Items - Components of Ac
Equity Items - Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Equity [Abstract] | ||||
Unrealized translation gain (loss), before tax | $ 27 | $ (5) | $ 110 | $ (22) |
Unrealized translation gain (loss), tax | 0 | 0 | (1) | 1 |
Unrealized translation gain (loss), net of tax | 27 | (5) | 109 | (21) |
Unrealized gain (loss) on commodity hedges, before tax | (4) | 6 | (9) | 1 |
Unrealized gain (loss) on commodity hedges, tax | 1 | (1) | 2 | 0 |
Unrealized gain (loss) on commodity hedges, net of tax | (3) | 5 | (7) | 1 |
Total other comprehensive income (loss), before tax | 23 | 1 | 101 | (21) |
Total other comprehensive income (loss), tax | 1 | (1) | 1 | 1 |
Other comprehensive income (loss) - Note N | $ 24 | $ 0 | $ 102 | $ (20) |
Equity Items - Summary of Recon
Equity Items - Summary of Reconciliation of Changes in Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 6 Months Ended | |||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | ||
Balance, end of period | $ 3,267 | $ 3,381 | $ 3,267 | $ 3,381 | |
Cash dividends declared per common share | $ 0.335 | $ 0.300 | $ 0.670 | $ 0.600 | |
Common Stock and Paid in Capital [Member] | |||||
Balance, beginning of period | $ 134 | $ 328 | $ 136 | $ 328 | |
Compensation expense and common shares issued | [1] | 4 | 4 | 2 | 4 |
Common shares purchased under repurchase program | [2],[3] | (138) | (155) | (138) | (155) |
Balance, end of period | 0 | 177 | 0 | 177 | |
Retained earnings [Member] | |||||
Balance, beginning of period | 3,675 | 2,827 | 3,653 | 2,796 | |
Net income | 91 | 786 | 132 | 834 | |
Regular dividends | (18) | (17) | (36) | (34) | |
Common shares purchased under repurchase program | [2] | (15) | 0 | (15) | 0 |
Other | 1 | 0 | 0 | 0 | |
Balance, end of period | 3,734 | 3,596 | 3,734 | 3,596 | |
Accumulated other comprehensive income (loss) [Member] | |||||
Balance, beginning of period | (491) | (392) | (569) | (372) | |
Unrealized translation gain (loss) | 27 | (5) | 109 | (21) | |
Unrealized gain (loss) on commodity hedges | (3) | 5 | (7) | 1 | |
Balance, end of period | $ (467) | $ (392) | $ (467) | $ (392) | |
[1] Common shares issued were 16,937 shares and 13,935 shares for the three months ended March 31, 2023 and 2022 , respectively, and 144,514 shares and 108,650 shares for the six months ended March 31, 2023 and 2022 , respectively. Common shares repurchased were 1,488,251 shares for the three and six months ended March 31, 2023, and 2,403,380 shares for the three and six months ended March 31, 2022. Includes $ 1 million in excise tax on stock repurchases for the three and six months ended March 31, 2023. |
Equity Items - Summary of Rec_2
Equity Items - Summary of Reconciliation of Changes in Stockholders' Equity (Parenthetical) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Equity [Abstract] | ||||
Common shares issued | 16,937 | 13,935 | 144,514 | 108,650 |
Common shares repurchased | 1,488,251 | 2,403,380 | 1,488,251 | 2,403,380 |
Excise tax on stock repurchases | $ 1 | $ 1 |
Stock Incentive Plans - Compone
Stock Incentive Plans - Components of Pre-Tax Stock-Based Compensation Expense Included in Continuing Operations (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||||||
Mar. 31, 2023 | [1] | Mar. 31, 2022 | [2] | Mar. 31, 2023 | [1] | Mar. 31, 2022 | [2] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Stock-based compensation | $ 6 | $ 5 | $ 14 | $ 11 | ||||
Nonvested Stock Awards [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Stock-based compensation | 4 | 2 | 7 | 6 | ||||
Performance Shares [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Stock-based compensation | $ 2 | $ 3 | $ 7 | $ 5 | ||||
[1] Included $ 1 million and $ 2 million of expense related to cash-settled nonvested restricted stock awards during the three and six months ended March 31, 2023 . Included zero and $ 2 million of expense related to cash-settled nonvested restricted stock awards during the three and six months ended March 31, 2022 . |
Stock Incentive Plans - Compo_2
Stock Incentive Plans - Components of Pre-Tax Stock-Based Compensation Expense Included in Continuing Operations (Parenthetical) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||||||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Stock-based compensation | $ 6 | [1] | $ 5 | [2] | $ 14 | [1] | $ 11 | [2] |
Cash-settled Nonvested Restricted Stock Awards [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Stock-based compensation | $ 1 | $ 0 | $ 2 | $ 2 | ||||
[1] Included $ 1 million and $ 2 million of expense related to cash-settled nonvested restricted stock awards during the three and six months ended March 31, 2023 . Included zero and $ 2 million of expense related to cash-settled nonvested restricted stock awards during the three and six months ended March 31, 2022 . |
Revenue - Disaggregation of Rev
Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Disaggregation Of Revenue [Line Items] | ||||
Sales | $ 603 | $ 604 | $ 1,128 | $ 1,115 |
Life Sciences [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 240 | 204 | 447 | 374 |
Life Sciences [Member] | North America [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 61 | 62 | 109 | 115 |
Life Sciences [Member] | Europe [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 87 | 66 | 160 | 121 |
Life Sciences [Member] | Asia Pacific [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 62 | 52 | 122 | 98 |
Life Sciences [Member] | Latin America & Other [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 30 | 24 | 56 | 40 |
Personal Care [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 167 | 172 | 305 | 318 |
Personal Care [Member] | North America [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 48 | 55 | 90 | 96 |
Personal Care [Member] | Europe [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 69 | 69 | 120 | 125 |
Personal Care [Member] | Asia Pacific [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 28 | 30 | 56 | 62 |
Personal Care [Member] | Latin America & Other [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 22 | 18 | 39 | 35 |
Specialty Additives [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 161 | 182 | 304 | 338 |
Specialty Additives [Member] | North America [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 52 | 61 | 105 | 114 |
Specialty Additives [Member] | Europe [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 61 | 69 | 109 | 125 |
Specialty Additives [Member] | Asia Pacific [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 39 | 45 | 74 | 85 |
Specialty Additives [Member] | Latin America & Other [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 9 | 7 | 16 | 14 |
Intermediates [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 51 | 66 | 105 | 119 |
Intermediates [Member] | North America [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 36 | 43 | 70 | 74 |
Intermediates [Member] | Europe [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 7 | 10 | 16 | 19 |
Intermediates [Member] | Asia Pacific [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | 6 | 11 | 14 | 21 |
Intermediates [Member] | Latin America & Other [Member] | ||||
Disaggregation Of Revenue [Line Items] | ||||
Sales | $ 2 | $ 2 | $ 5 | $ 5 |
Revenue - Additional Informatio
Revenue - Additional Information (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Trade Receivable [Member] | ||
Revenue From Contracts With Customers [Line Items] | ||
Trade receivables | $ 365 | $ 369 |
Reportable Segment Informatio_2
Reportable Segment Information - Summary of Financial Information for Each Reportable Segment (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Sep. 30, 2022 | ||
Segment Reporting Information [Line Items] | ||||||
SALES | $ 603 | $ 604 | $ 1,128 | $ 1,115 | ||
OPERATING INCOME (LOSS) | 83 | 100 | 120 | 142 | ||
DEPRECIATION EXPENSE | 37 | 37 | 74 | 74 | ||
AMORTIZATION EXPENSE | 23 | 24 | 46 | 47 | ||
EBITDA | [1] | 143 | 161 | 240 | 263 | |
TOTAL ASSETS | 6,183 | 6,183 | $ 6,213 | |||
Intersegment Eliminations [Member] | ||||||
Segment Reporting Information [Line Items] | ||||||
SALES | [2] | (16) | (20) | (33) | (34) | |
Life Sciences [Member] | ||||||
Segment Reporting Information [Line Items] | ||||||
SALES | 240 | 204 | 447 | 374 | ||
OPERATING INCOME (LOSS) | 58 | 43 | 92 | 64 | ||
DEPRECIATION EXPENSE | 10 | 8 | 20 | 16 | ||
AMORTIZATION EXPENSE | 7 | 7 | 14 | 14 | ||
EBITDA | [1] | 75 | 58 | 126 | 94 | |
TOTAL ASSETS | 1,964 | 1,964 | 1,905 | |||
Personal Care [Member] | ||||||
Segment Reporting Information [Line Items] | ||||||
SALES | 167 | 172 | 305 | 318 | ||
OPERATING INCOME (LOSS) | 14 | 28 | 25 | 42 | ||
DEPRECIATION EXPENSE | 10 | 9 | 20 | 18 | ||
AMORTIZATION EXPENSE | 11 | 12 | 22 | 24 | ||
EBITDA | [1] | 35 | 49 | 67 | 84 | |
TOTAL ASSETS | 1,079 | 1,079 | 1,073 | |||
Specialty Additives [Member] | ||||||
Segment Reporting Information [Line Items] | ||||||
SALES | 161 | 182 | 304 | 338 | ||
OPERATING INCOME (LOSS) | 15 | 26 | 16 | 44 | ||
DEPRECIATION EXPENSE | 14 | 17 | 28 | 33 | ||
AMORTIZATION EXPENSE | 5 | 5 | 9 | 9 | ||
EBITDA | [1] | 34 | 48 | 53 | 86 | |
TOTAL ASSETS | 1,664 | 1,664 | 1,567 | |||
Intermediates [Member] | ||||||
Segment Reporting Information [Line Items] | ||||||
SALES | 51 | 66 | 105 | 119 | ||
OPERATING INCOME (LOSS) | 17 | 27 | 37 | 42 | ||
DEPRECIATION EXPENSE | 3 | 3 | 6 | 7 | ||
AMORTIZATION EXPENSE | 0 | 0 | 1 | 0 | ||
EBITDA | [1] | 20 | 30 | 44 | 49 | |
TOTAL ASSETS | 172 | 172 | 170 | |||
Unallocated and Other [Member] | ||||||
Segment Reporting Information [Line Items] | ||||||
OPERATING INCOME (LOSS) | (21) | (24) | (50) | (50) | ||
EBITDA | [1] | (21) | $ (24) | (50) | $ (50) | |
TOTAL ASSETS | $ 1,304 | $ 1,304 | $ 1,498 | |||
[1] Excludes income (loss) from discontinued operations and other net periodic benefit loss (income). See the Statement of Consolidated Comprehensive Income (Loss) for applicable amounts excluded. Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost. |